<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/264696-vla-4-antagonists by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:27:51 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 264696:&quot;VLA-4 ANTAGONISTS&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;VLA-4 ANTAGONISTS&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Compounds of Formula (I) are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn&#x27;s disease, multiple sclerosis, asthma, and rheumatoid arthritis.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>compounds of the present invention demonstrate significant receptor occupancy of VLA-4 bearing cells<br>
after oral administration and are suitable for once-, twice-, or thrice-a-day oral administration. This<br>
invention also relates to compositions containing such compounds and methods of treatment using such<br>
compounds.<br>
DETAILED DESCRIPTION OF THE INVENTION<br>
The present invention provides a compound of formula I:<br>
or a pharmaceutically acceptable salt thereof, wherein:<br>
AisNorN+-O-;<br>
X and Y are independently selected from halogen, Ci_3alkyl, and Ci_3alkoxy;<br>
R1 is selected from (1) hydrogen, (2) C1-10alkyl, (3) -(C1-10alkyl)-aryl, (4) alkyl)-O-Ci-i oa-lk(Cy=l,<br>
(5) -(C1-10alkyl)-OC(0)-C1-10alkyl, (6) -(C1-10aIkyl)-OC(O)-aryI, (7) -(C1-10alkyl)-OC(O)OC1-<br>
10alkyl, and (8) -(C1-10alkyl)-N+(C1-3alkyl)3; wherein alkyl is optionally substituted with one to<br>
three substituents independently selected from Ra, and aryl is optionally substituted with one to three<br>
substituents independently selected from Rb;<br>
R-2 is hydrogen or methyl;<br>
one of R3 and R4 is hydrogen, and the other is<br>
R6<br>
R5<br>
k is 0 to 4;<br>
R5 and R6 are independently selected from hydrogen, fluorine, CF3, and CO2Rf, with the proviso that<br>
R5 and R6 are not both hydrogen;<br>
R? and R8 are independently selected from H, -SO2-C1-3alkyl, CN, CF3, OCF3, and halogen;<br>
Ra is selected from (1) -ORd, (2) -NRdS(O)mRe, (3) -NO2, (4) halogen, (5) -S(O)mRd, (6) -SRd,<br>
(7) -S(0)20Rd, (8) -S(0)mNRdRe, (9) -NRdRe, (10) -CXCRfRgfoNR'fc6, (11) -C(O)Rd (12) -CO2Rd,<br>
(13) -C02CRfRg)nCONRdRe, (14) -OC(O)Rd, (15) -CN, (16) -C(O)NRdRe, (17) -NRdC(O)Re,<br>
(18) -OC(0)NRdRe, (19) -NRdC(0)ORe, (20) -NRdC(O)NRdRe, (21) -CRd(N-ORe), (22) CF3, <br>
OCF3, (24) C3-8-8cycloalkyl, and (25) heterocyclyl; wherein cycloalkyl and heterocyclyl are optionally<br>
substituted with one to three groups independently selected from Rc;<br>
Rb is selected from (1) a group selected from Ra, (2) C1-10 alkyl, (3) C2-10 alkenyl (4) C2-10 alkynyl,<br>
(5) aryl, and (6) -(C1-10alkyl)-aryl, wherein alkyl, alkenyl, alkynyl, and aryl are optionally substituted<br>
with one to three substituents selected from a group independently selected from Rc;<br>
Rc is (1) halogen, (2) amino, (3) carboxy, (4) Chalky!, (5) Ci-4alkoxy, (6) aryl, (7) -(C1-4alkyl)-aryl,<br>
(8) hydroxy, (9) CFs, (10) OC(O)CMalkyl, (11) OC(O)NRfRg, or (12) aryloxy;<br>
Rd and Re are independently selected from hydrogen, C1-10alkyl, C2-10alkenyl, C2-l()alkynyl, Cy<br>
and -(C1-10alkyl)-Cy, wherein alkyl, alkenyl, alkynyl and Cy are optionally substituted with one to four<br>
substituents independently selected from Rc; or<br>
Rd and Re together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7<br>
members containing 0-2 additional heteroatoms independently selected from O, S and N-Rn;<br>
R^and RÂ§ are independently selected from hydrogen, C1-10alkyl, Cy and -(C1-10alkyl)-Cy; or<br>
Rf and Rg together with the carbon to which they are attached form a ring of 5 to 7 members containing<br>
0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;<br>
Rh is selected from Rf and -C(O)Rf;<br>
Cy is selected from cycloalkyl, heterocyclyl, aryl, and heteroaryl;<br>
m is 1 or 2; and<br>
n is 2 to 5.<br>
hi one subset of formula I are compounds wherein one of X and Y is halogen and the<br>
other is selected from halogen, C1-3alkyl and C=alkoxy. In one embodiment thereof X and Y are each<br>
halogen, preferably each is chlorine.<br>
In another subset of formula I are compounds wherein Rl is hydrogen, Ci_<br>
4alkyl, -(C1-4alkyl)OC1-4alkyl, or -(CaUcyl)N+(Ci-3alkyl)3. In one embodiment Rl is selected from-3<br>
hydrogen, methyl, ethyl, 2-methoxyethyl, and 2-(trimethylaminium)ethyl.<br>
hi a third subset of formula I are compounds wherein one of R3 and R4 is hydrogen, and<br>
the other is selected from<br>
wherein one of R.5 and R.6 is F and the other is H or F, k is 0 to 4, and k' is 0 to 2. In one embodiment<br>
thereof the non-hydrogen substituent is selected from 3,3-difluoro-l-azetidinyl, 3,3-difluoro-lpyrrolidinyl,<br>
3,3-difluoro-l-piperidinyl, 3-fluoro-l-azetidinyl, 3-fluoro-l-pyrrolidinyl, 3-fluoro-lpiperidinyl,<br>
4,4-difluoro-l-piperidinyl, 4-fluoro-l-piperidinyl, 2-trifluoromethyl-l-pyrrolidinyl, 2-<br>
carboxy-1-pyrrolidinyl, and 2-(t-butoxycarbonyi)-l-pyrrolidinyL<br>
In a fourth subset of formula 1 are compounds having the formula la:<br>
la<br>
or a pharmaceutically acceptable, salt thereof, wherein<br>
AisNorN+O;<br>
Rl is selected from hydrogen, Ci-iQalkyl, -(Cijalkyl)-aryl, -Ci.4alkyl)-O-Ci_4alkyl, and<br>
one of R and R4 is hydrogen and the other is selected from<br>
wherein one of R5 and R6 is F and the other is H or F, k is 0 to 4, and k' is 0 to 2; R? and R8 are<br>
independently selected from H, SO2-Ci_3alkyl, CN, CF3, OCF3, and halogen. Preferably k is 0 to 2.<br>
In one embodiment of formula la are compounds wherein R3 is hydrogen and R4 is<br>
selected from 3,3-difluoro-l-azetidinyl, 3,3-difluoro-l-pyrrolidinyl, 3,3-difluoro-l-piperidinyl, 3-fluorol-<br>
azetidinyl, 3-fluoro-l-pyrrolidinyl, 3-fluoro-l-piperidinyl, 4,4-difluoro-l-piperidmyl, 4-fluoro-lpiperidinyl,<br>
2-trifluoromethyl-l-pyrrolidinyl. In a second embodiment of formula la are compounds<br>
wherein R4 is hydrogen and R3 is selected from 3,3-difluoro-l-azetidinyI, 3,3-difluoro-l-pyrrolidinyl,<br>
3,3-difluoro-l-piperidinyl, 3-fluoro-l-azetidinyl., 3-fluoro-l-pyrrolidinyl, 3-fluoro-l-piperidinyl, 4,4-<br>
difluoro-1-piperiduiyl, 4-fluoro-l-piperidinyl, 2-trifiuoromethyI-l-pyrrolidinyl, 2-carboxy-l-pyrrolidinyl,<br>
and 2-(t-butoxycarbonyl)-l-pyrrolidinyl.<br>
In another aspect the present invention provides a method for the prevention or treatment<br>
of diseases, disorders, conditions or symptoms mediated by cell adhesion in a mammal which comprises<br>
administering to said mammal an effective amount of a compound of formula I or a pharmaceutically<br>
acceptable salt thereof. This aspect includes the use of a compound of formula I or a pharmaceutically<br>
acceptable salt thereof in the manufacture of a medicament for the treatment of diseases, disorders,<br>
conditions or symptoms mediated by cell adhesion in a mammal. In one embodiment said disease or<br>
disorder is selected from asthma, allergic rhinitis, multiple sclerosis, atherosclerosis, inflammatory bowel<br>
disease, rheumatoid arthritis, organ transplantation, acute leukemia, and sickle cell anemia.<br>
In another aspect the present invention provides a method for preventing the action of<br>
VLA-4 in a mammal which comprises administering to said mammal a therapeutically effective amount<br>
of a compound of formula I or a pharmaceutically acceptable salt thereof. This aspect includes the use of<br>
a compound of formula I in the manufacture of a medicament for preventing the action of VLA-4 in a<br>
mammal.<br>
Another aspect of the present invention provides a pharmaceutical composition which<br>
comprises a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically<br>
acceptable carrier.<br>
"Alkyl", as well as other groups having the prefix "alk", such as alkoxy, alkanoyl, means<br>
carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups<br>
include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and<br>
the like.<br>
"Alkenyl" means carbon chains which contain at least one carbon-carbon double bond,<br>
and which may be linear or branched or combinations thereof. Examples of alkenyl include vinyl, allyl,<br>
isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.<br>
"Alkynyl" means carbon chains which contain at least one carbon-carbon triple bond,<br>
and which may be linear or branched or combinations thereof. Examples of alkynyl include ethynyl,<br>
propargyl, 3-methyl-l-pentynyl, 2-heptynyl and the like.<br>
"Cycloalkyl" means mono- or bicyclic saturated carbocyclic rings, each of which having<br>
from 3 to 10 carbon atoms. The term also includes monocyclic rings fused to an aryl group in which the<br>
point of attachment is on the non-aromatic portion. Examples of cycloalkyi include cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, and<br>
the like.<br>
"Aryl" means mono- or bicyclic aromatic rings containing only carbon atoms. The term<br>
also includes aryl group fused to a monocyclic cycloalkyi or monocyclic heterocyclyl group in which the<br>
point of attachment is on the aromatic portion. Examples of aryl include phenyl, naphthyl, indanyl,<br>
indenyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, 1,4-benzodioxanyl, and the<br>
like.<br>
"HeteroaryJ" means a mono- or bicyclic aromatic ring containing at least one heteroatom<br>
selected from N, O and S, with each ring containing 5 to 6 atoms. Examples of heteroaryl include<br>
pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl,<br>
imidazolyl, triazolyl, tetrazolyl, fiiranyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl,<br>
benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo(2,3-b)pyridyl,<br>
quinolyl, indolyl, isoquinolyl, and the like.<br>
"Heterocyclyl" means mono- or bicyclic saturated rings containing at least one<br>
heteroatom selected from N, S and O, each of said ring having from 3 to 10 atoms in which the point of<br>
attachment may be carbon or nitrogen. The term also includes monocyclic heterocycle fused to an aryl or<br>
heteroaryl group in which the point of attachment is on the non-aromatic portion. Examples of<br>
"heterocycryl" include pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, 2,3-dihydrofuro(2,3-<br>
b)pyridyl, benzoxazinyl, tetrahydrohydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl, and the<br>
like. The term also includes partially unsaturated monocyclic rings that are not aromatic, such as 2- or 4-<br>
pyridones attached through the nitrogen or N-substituted-(lH,3H)-pyrimidine-2,4-diones (N-substituted<br>
uracils).<br>
"Halogen" includes fluorine, chlorine, bromine and iodine.<br>
Optical Isomers - Diastereomers - Geometric Isomers - Tautomers<br>
Compounds of Formula I contain one or more asymmetric centers and can thus occur as<br>
racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual<br>
diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds<br>
of Formula I.<br>
Some of the compounds described herein contain olefinic double bonds, and unless<br>
specified otherwise, are meant to include both E and Z geometric isomers.<br>
Some of the compounds described herein may exist with different points of attachment<br>
of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as<br>
keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with<br>
compounds of Formula I.<br>
Compounds of the Formula I may be separated into diastereoisomeric pairs of<br>
enantiomers by, for example, fractional crystallization from a suitable solvent, for example MeOH or<br>
EtOAc or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual<br>
stereoisomers by conventional means, for example by the use of an optically active amine as a resolving<br>
agent or on a chiral HPLC column.<br>
Alternatively, any enantiomer of a compound of the general Formula I or la may be<br>
obtained by stereospecific synthesis using optically pure starting materials or reagents of known<br>
configuration.<br>
Salts<br>
The term "pharmaceutically acceptable salts" refers to salts prepared from<br>
pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic<br>
or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper,<br>
ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.<br>
Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts<br>
derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary,<br>
and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines,<br>
and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine,<br>
diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine,<br>
N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidihe, hydrabamine, isopropylamine,<br>
lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines,<br>
theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.<br>
When the compound of the present invention is basic, salts may be prepared from<br>
pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include<br>
acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic,<br>
hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric,<br>
pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.<br>
Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric<br>
acids.<br>
It will be understood that, as used herein, references to the compounds of Formula I are<br>
meant to also include the pharmaceutically acceptable salts.<br>
Utilities<br>
The ability of the compounds of Formula I to antagonize the actions of VLA-4 integrin<br>
makes them useful for preventing or reversing the symptoms, disorders or diseases induced by the<br>
binding of VLA-4 to its various ligands. Thus, these antagonists will inhibit cell adhesion processes<br>
including cell activation, migration, proliferation and differentiation. Accordingly, another aspect of the<br>
present invention provides a method for the treatment (including prevention, alleviation, amelioration or<br>
suppression) of diseases or disorders or symptoms mediated by VLA-4 binding and cell adhesion and<br>
activation, which comprises administering to a mammal an effective amount of a compound of Formula I.<br>
Such diseases, disorders, conditions or symptoms are, for example (1) multiple sclerosis, (2) asthma, (3)<br>
allergic rhinitis, (4) allergic conjunctivitis, (5) inflammatory lung diseases, (6) rheumatoid arthritis, (7)<br>
septic arthritis, (8) type I diabetes, (9) organ transplantation rejection, (10) restenosis, (11) autologous<br>
bone marrow transplantation, (12) inflammatory sequelae of viral infections, (13) myocarditis, (14)<br>
inflammatory bowel disease including ulcerative colitis and Crohn's disease, (15) certain types of toxic<br>
and immune-based nephritis, (16) contact dermal hypersensitivity, (17) psoriasis, (18) tumor metastasis,<br>
 (19) atherosclerosis, (20) sickle cell anemia, (21) certain acute leukemias, (22) various melanomas,<br>
carcinomas and sarcomas (including multiple myeloma); (23) acute respiratory distress syndrome; (24)<br>
uveitis; (25) circulatory shock; and (26) hepatitis.<br>
The utilities of the present compounds in these diseases or disorders may be<br>
demonstrated hi animal disease models that have been reported in the literature. The following are<br>
examples of such animal disease models: i) experimental allergic encephalomyelitis, a model of neuronal<br>
demyelination resembling multiple sclerosis (for example, see T. Yednock et al., Nature, 356, 63 (1993)<br>
and E. Keszthelyi et al., Neurology. 47,1053 (1996)); ii) bronchial hyperresponsiveness in sheep and<br>
guinea pigs as models for the various phases of asthma (for example, see W. M. Abraham et al., J. Clin.<br>
Invest. 91 776 (1993) and A. A. Y. Milne and P. P. Piper, Eur. J. Pharmacol.. 282. 243 (1995));<br>
iii) adjuvant-induced arthritis in rats as a model of inflammatory arthritis (see C. Barbadillo et al., Arthr.<br>
Rheuma. (Suppl.), 36 95 (1993) and D. Seiffge, J. Rheumatol.. 23, 12 (1996)); iv) adoptive autoimmune<br>
diabetes in the NOD mouse (see J. L. Baron et al., J. Clin. Invest.. 93,1700 (1994), A. Jakubowski et al.,<br>
J. ImmunoL 155. 938 (1995), and X. D. Yang et al., Diabetes. 46,1542 (1997)); v) cardiac allograft<br>
survival in mice as a model of organ transplantation (see M. Isobe et al., Tranplant. Proc.. 26. 867 (1994)<br>
and S. Molossi et al., J. Clin Invest. 95. 2601 (1995)); vi) spontaneous chronic colitis hi cotton-top<br>
tamarins which resembles human ulcerative colitis, a form of inflammatory bowel disease (see D. K.<br>
Podolsky et al., J. Clin. Invest.. 92, 372 (1993)); vii) contact hypersensitivity models as a model for skin<br>
allergic reactions (see T. A. Ferguson and T. S. Kupper, J. Immunol. 150. 1172 (1993) and P. L.<br>
Chisholm et al., Eur. J. Immunol.. 23.682 (1993)); viii) acute nephrotoxic nephritis (see M. S. Mulligan<br>
et al., J. Clin. Invest.. 91. 577 (1993)); ix) tumor metastasis (for examples, see M. Edward, Curr. Opin.<br>
Oncol., 7,185 (1995)); x) experimental autoimmune thyroiditis (see R. W. McMurray et al.,<br>
Autoimmunity, 23.9 (1996); xi) ischemic tissue damage following arterial occlusion in rats (see F.<br>
Squadrito et al., Eur. J. Pharmacol.. 318.153 (1996)); xii) inhibition of TFI2 T-cell cytokine production<br>
including DL-4 and IL-5 by VLA-4 antibodies which would attenuate allergic responses (J.Clinical<br>
Investigation 100,3083 (1997); xiii) antibodies to VLA-4 integrin mobilize long term repopulating cells<br>
and augment cytokine-induced mobilizationin primates and mice (Blood. 90 4779-4788 (1997); xiv)<br>
sickle reticulocytes adhere to VCAM-1 (Blood 85 268-274 (1995) and Blood 88 4348-4358(1996);<br>
xv) chemokine stromal cell derived factor 1 modulates VLA-4 integrin mediated multiple myeloma cell<br>
adhesion to CS-1/fibronectin and VCAM-1 (Blood. 97. 346-351 2001)<br>
Dose Ranges<br>
The magnitude of prophylactic or therapeutic dose of a compound of Formula I will, of<br>
course, vary with the nature and severity of the condition to be treated, and with the particular compound<br>
of Formula I used and its route of administration. The dose will also vary according to the age, weight<br>
and response of the individual patient. In general, the daily dose range lie within the range of from about<br>
0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 50 mg per kg,<br>
and most preferably 0.1 to 10 mg per kg, in single or divided doses. On the other hand, it may be<br>
necessary to use dosages outside these limits in some cases.<br>
For use where a composition for intravenous administration is employed, a suitable<br>
dosage range is from about 0.01 mg to about 25 mg (preferably from 0.1 mg to about 10 mg) of a<br>
compound of Formula I per kg of body weight per day.<br>
In the case where an oral composition is employed, a suitable dosage range is, e.g. from<br>
about 0.01 mg to about 100 mg of a compound of Formula I per kg of body weight per day, preferably<br>
from about 0.1 mg to about 10 mg per kg.<br>
For use where a composition for sublingual administration is employed, a suitable<br>
dosage range is from 0.01 mg to about 25 mg (preferably from 0.1 mg to about 5 mg) of a compound of<br>
Formula I per kg of body weight per day.<br>
For the treatment of asthma, a compound of Formula I may be used at a dose of from<br>
about 0.1 mg/kg to about 100 mg/kg, preferably from about 1 mg/kg to 10 mg/kg, by<br>
oral/inhalation/sublingual/etc. once, twice, three times daily, etc. The dose may be adminstered as a<br>
single daily dose or divided for twice or thrice daily administration.<br>
For the treatment of multiple sclerosis, a compound of Formula I may be used at a dose<br>
of from about 0.1 mg/kg to about 100 mg/kg, preferably from about 1 mg/kg to 10 mg/kg, by<br>
oral/inhalation/sublingual/etc. once, twice, three times daily, etc. The dose may be adminstered as a<br>
single daily dose or divided for twice or thrice daily administration.<br>
For the treatment of inflammatory bowel disease, a compound of Formula I may be used<br>
at a dose of from about 0.1 mg/kg to about 100 mg/kg, preferably from about 1 mg/kg to 10 mg/kg, by<br>
oral/inhalation/etc, once, twice, three times daily, etc. The dose may be adminstered as a single daily<br>
dose or divided for twice or thrice daily administration.<br>
For the treatment of rheumatoid arthritis, a compound of Formula I may be used at a<br>
dose of from about 0.1 mg/kg to about 100 mg/kg, preferably from about 1 mg/kg to 10 mg/kg, by<br>
oral/inhalation/sublingual/etc. once, twice, three times daily, etc. The dose may be adminstered as a<br>
single daily dose or divided for twice or thrice daily administration.<br>
Pharmaceutical Compositions<br>
Another aspect of the present invention provides pharmaceutical compositions which<br>
comprises a compound of Formula I and a pharmaceutically acceptable carrier. The term "composition",<br>
as in pharmaceutical composition, is intended to encompass a product comprising the active<br>
ingredients), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the<br>
carrier, as well as any product which results, directly or indirectly, from combination, complexation or<br>
aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients,<br>
or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the<br>
pharmaceutical compositions of the present invention encompass any composition made by admixing a<br>
compound of Formula I, additional active ingredients), and pharmaceutically acceptable excipients.<br>
Any suitable route of administration may be employed for providing a mammal,<br>
especially a human with an effective dosage of a compound of the present invention. For example, oral,<br>
sublingual, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage<br>
forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols,<br>
and the like.<br>
The pharmaceutical compositions of the present invention comprise a compound of<br>
Formula I as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a<br>
pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term<br>
"pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic<br>
bases or acids including inorganic bases or acids and organic bases or acids.<br>
The compositions include compositions suitable for oral, sublingual, rectal, topical,<br>
parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary<br>
(aerosol inhalation), or nasal administration, although the most suitable route in any given case will<br>
depend on the nature and severity of the conditions being treated and on the nature of the active<br>
ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods<br>
well-known in the art of pharmacy.<br>
For administration by inhalation, the compounds of the present invention are<br>
conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulizers.<br>
The compounds may also be delivered as powders which may be formulated and the powder composition<br>
may be inhaled with the aid of an insufflation powder inhaler device. The preferred delivery systems for<br>
inhalation are metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or<br>
solution of a compound of Formula I in suitable propellants, such as fluorocarbons or hydrocarbons and<br>
dry powder inhalation (DPI) aerosol, which may be formulated as a dry powder of a compound of<br>
Formula I with or without additional excipients<br>
Suitable topical formulations of a compound of formula I include transdermal devices,<br>
aerosols, creams, ointments, lotions, dusting powders, and the like.<br>
In practical use, the compounds of Formula I can be combined as the active ingredient in<br>
intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding<br>
techniques. The carrier may take a wide variety of forms depending on the form of preparation desired<br>
for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral<br>
dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water,<br>
glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral<br>
liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches,<br>
sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents<br>
and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets,<br>
with the solid oral preparations being preferred over the liquid preparations. Because of their ease of<br>
administration, tablets and capsules represent the most advantageous oral dosage unit form in which case<br>
solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard<br>
aqueous or nonaqueous techniques.<br>
In addition to the common dosage forms set out above, the compounds of Formula I may<br>
also be administered by controlled release means and/or delivery devices such as those described in U.S.<br>
Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200 and 4,008,719.<br>
Pharmaceutical compositions of the present invention suitable for oral administration<br>
may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined<br>
amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous<br>
liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such<br>
compositions may be prepared by any of the methods of pharmacy but all methods include the step of<br>
bringing into association the active ingredient with the carrier which constitutes one or more necessary<br>
ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active<br>
ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the<br>
product into the desired presentation. For example, a tablet may be prepared by compression or molding,<br>
optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing<br>
in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally<br>
mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be<br>
made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert<br>
liquid diluent. Desirably, each tablet contains from about 1 mg to about 500 mg of the active ingredient<br>
and each cachet or capsule contains from about 1 to about 500 mg of the active ingredient.<br>
The following are examples of representative pharmaceutical dosage forms for the<br>
(Figure Removed)  Compounds of Formula I may be used in combination with other drugs that are used in<br>
the treatment/prevention/suppression or amelioration of the diseases or conditions for which compounds<br>
of Formula I are useful. Such other drugs may be administered, by a route and in an amount commonly<br>
used therefor, contemporaneously or sequentially with a compound of Formula I. When a compound of<br>
Formula I is used contemporaneously with one or more other drugs, a pharmaceutical composition<br>
containing such other drugs in addition to the compound of Formula I is preferred. Accordingly, the<br>
pharmaceutical compositions of the present invention include those that also contain one or more other<br>
active ingredients, in addition to a compound of Formula I. Examples of other active ingredients that<br>
may be combined with a compound of Formula I, either administered separately or in the same<br>
pharmaceutical compositions, include, but are not limited to: (a) other VLA-4 antagonists such as those<br>
described in US 5,510,332, WO97/03094, WO97/02289, WO96/40781, WO96/22966, WO96/20216,<br>
WO96/01644, WO96/06108, WO95/15973 and WO96/31206, as well as natalizumab; (b) steroids such<br>
as beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and<br>
hydrocortisone; (c) immunosuppressants such as cyclosporin, tacrolimus, rapamycin and other FK-506<br>
type immunosuppressants; (d) antihistamines (Hl-histamine antagonists) such as bromopheniramine,<br>
chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline,<br>
tripelennamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine,<br>
antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, fexofenadine,<br>
descarboethoxyloratadine, and the like; (e) non-steroidal anti-asthmatics such as p2-agonists (terbutaline,<br>
metaproterenol, fenoterol, isoetharine, albuterol, bitolterol, salmeterol and pirbuterol), theophylline,<br>
cromolyn sodium, atropine, ipratropium bromide, leukotriene antagonists (zafirlukast, montelukast,<br>
pranlukast, iralukast, pobilukast, SKB-106,203), leukotriene biosynthesis inhibitors (zileuton, BAY-<br>
1005); (f) non-steroidal antiinflamniatory agents (NSAIDs) such as propionic acid derivatives<br>
(alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen,<br>
ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen,<br>
tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac,<br>
clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac,<br>
sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid,<br>
meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid<br>
derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxican),<br>
salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone,<br>
mofebutazone, oxyphenbutazone, phenylbutazone); (g) cyclooxygenase-2 (COX-2) inhibitors such as<br>
celecoxib, rofecoxib, and parecoxib; (h) inhibitors of phosphodiesterase type IV (PDE-TV); (i)<br>
antagonists of the chemokine receptors, especially CCR-1, CCR-2, and CCR-3; (j) cholesterol lowering<br>
agents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin,<br>
atorvastatin, and other statins), sequestrants (cholestyramine and colestipol), nicotinic acid, fenofibric<br>
acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzafibrate), and probucol; (k) anti-diabetic<br>
agents such as insulin, sulfonylureas, biguanides (metfonnin), a-glucosidase inhibitors (acarbose) and<br>
glitazones (troglitazone, pioglitazone, englitazone, MCC-555, BRL49653 and the like); (1) preparations<br>
of interferon beta (interferon beta-la, interferon beta-lb); (m) anticholinergic agents such as muscarinic<br>
antagonists (ipratropium and tiatropium); (n) current treatments for multiple sclerosis, including<br>
prednisolone, glatiramer, deoxyadenosine, mitoxantrone, methotrexate, and cyclophosphamide; (o) p38<br>
kinase inhibitors; (p) other compounds such as 5-aminosalicylic acid and prodrugs thereof,<br>
antimetabolites such as azathioprine and 6-mercaptopurine, and cytotoxic cancer chemotherapeutic<br>
agents.<br>
The weight ratio of the compound of the Formula I to the second active ingredient may<br>
be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of<br>
each will be used. Thus, for example, when a compound of the Formula I is combined with an NSACD<br>
the weight ratio of the compound of the Formula I to the NSAED will generally range from about 1000:1<br>
to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the Formula I<br>
and other active ingredients will generally also be within the aforementioned range, but in each case, an<br>
effective dose of each active ingredient should be used.<br>
Abbreviations that may be used in the following Schemes and Examples include:<br>
4-DMAP: 4-dimethylaminopyridine; AcCN: acetonitrile; BOG: tert-butoxycarbonyl; BOC-ON:2-(tertbutoxycarbonyloxyimino)-<br>
2-phenylacetonitrile; BOP: benzotriazol-1 -yloxy-tris(dimethylamino)-<br>
phosphonium hexafluorophosphate; brine: saturated NaCl solution; DDPEA: N,N-diisopropylethyIamine;<br>
DMF: dimethylformamide; DMSO: dimethylsulfoxide; Et: ethyl; EtOAc: ethyl acetate; EtOH: ethanol; g<br>
or gm: gram; h or hr: hours; HATU: C)-(7-azabenzotria2Kl-l-y])-J/,7,3)3-tetramethyluronium hexafluorophosphate;<br>
HBTU: O-(benzotriazoI-l-yl)-l,l,3,3-tetraraethyluronium hexafluorophosphate; HOAc:<br>
acetic acid; HOAt: l-hydroxy-7-azabenzotriazole; HOBt: 1-hydroxybenzotriazole; HPLC: high pressure<br>
liquid chromatography; in vacua: rotoevaporation; Me: methyl; MeOH: methanol; mg: milligram; MHz:<br>
megahertz; min: minutes; mL: milliliter; mmol: millimole; MS orms: mass spectrum; MsCl: methanesulfonyl<br>
chloride; Ph: phenyl; Pb/jP: triphenylphosphine; PyBOP: (benzotriazol-l-yloxy)tripyrrolidinophosphonium<br>
hexafluorophosphate; it: room temperature; TEA: triethylamine; TFA: trifluoroacetic acid;<br>
THF: tetrahydrofuran.<br>
Compounds of the present invention may be prepared by procedures illustrated in the<br>
accompanying schemes. In Scheme 1, a substituted pyridyl-4-carboxylic acid derivative A is treated with<br>
thionyl chloride to make the carboxylic acid chloride derivative which is then reacted with a 4-amino-<br>
(L)-phenylalanine derivative to yield the amide B. The N-BOC-protecting group in B is removed with<br>
strong acid (TFA or HC1) to afford the free amine C.<br>
In Scheme 2, an appropriately substituted (Lproline ester D (R'=H) is sulfonylated with 3-cyanobenzenesulfonyl<br>
chloride L in the presence of base (DJPEA or Na2CO3) to yield sulfonamide E which, if<br>
containing an ester protecting group, is treated with hydroxide to afford the free acid. Amine C and acid<br>
E are reacted together in the presence of an appropriate coupling agent (eg., PyBOP, HBTU/HOAt, or E<br>
may be first converted to the corresponding acid chloride) to afford amide F. Alternatively, the proline<br>
ester D (R'=BOC) is hydrolyzed to the corresponding acid by treatment with a base such as LiOH. The<br>
acid is then coupled with C, as described above, to give M, following the removal of the BOC group.<br>
The amine M is then sulfonylated with L in the presence of a base to provide F. The ester in F can be<br>
(Figure Removed)Biological Evaluation<br>
Compounds of formula I are potent antagonists of VLA-4 with significant and sustained<br>
receptor occupancy on VLA-4 bearing cells. The rate of dissociation of a test compound from Jurkat cells may be determined by the method described in G. Doherty et al., Bioorganic &amp; Medicinal<br>
Chemistry Letters, 13, 1891 (2003). Compounds of the present invention had half-lives of dissociation of<br>
greater than three hours (tj/2 3 hr) in this assay, demonstrating they are tight binding inhibitors of<br>
VLA-4 receptor occupancy after oral dosing in rats and dogs may be determined by the<br>
method described in D. R. Leone et al., J. Pharmacol. Exper. Therap., 305, 1150 (2003). Compounds of<br>
the present invention demonstrated sustained and significant receptor occupancy (&gt;50%) after oral<br>
dosing.<br>
Compounds of the present invention may be prepared by procedures detailed in the<br>
following examples. The examples provided are illustrative of the present invention and are not to be<br>
construed as limiting its scope in any manner:<br>
REFERENCE EXAMPLE 1<br>
4-(Y3', S'-DichloroisonicotinovDaminoHLVphenylalanine. Ethyl Ester, HCI<br>
HCI H2N<br>
Step A: To 500 mL of absolute ethanol under nitrogen at 0Â°C was added thionyl chloride (21 mL, 0.29<br>
mol) over 5 min, and the clear solution was stirred at 0Â°C for 10 min and then at rt for 30 min. 4-Nitro-<br>
L-phenylalanine (50.2 g, 0.24 mol) was added in one portion, and the mixture was refluxed overnight.<br>
The resulting mixture was concentrated in vacuo to give 4-nitro-L-phenylalanine, ethyl ester, HCI (60 g)<br>
as a white solid. lH NMR (400 MHz, CD3OD) 5 8.21 (d, 2H), 7.54 (d, 2H), 4.39 (dd, IH), 4.22 (q, 2H),<br>
3.24-3.40 (m, 2H), 1.22 (t, 3H).<br>
Step B: To a suspension of the compound of Step A (60 g, 0.22 mol) in methylene chloride (1.5 L) under<br>
nitrogen was added TEA (31 mL). After stirring at rt for 10 min, di-f-butyl dicarbonate (49 g, 0.22 mol)<br>
and 4-DMAP (0.1 g) was added, and the reaction mixture was stirred at rt overnight, washed with IN<br>
HCI (2x 200 mL), H2O (2x 200 mL) and brine (1 X 250 mL), dried over anhydrous Na2SO4, filtered and<br>
concentrated to afford N-BOC-4-nitro-L-phenylalanine, ethyl ester (78 g). IH NMR (400 MHz, CDCls)<br>
5 8.14 (d, 2H), 7.28 (d, 2H), 4.30-4.65 (m, IH), 4.15 (q, 2H), 3.00-3.30 (m, 2H), 1.35 (s, 9H), 1.20 (t,3H).<br>
Step C: A solution of the compound of Step B (78.3 g, 0.22 mol) in absolute ethanol (300 mL) was<br>
purged with nitrogen, and 10% palladium on carbon (1.0 g) was added. After hydrogenated at 40-50 psi<br>
for 1 h, the reaction mixture was filtered through Celite, and the cake was washed with EtOH followed<br>
by EtOAc. The filtrate was concentrated, and the residue was purified by flash column chromatography<br>
on silica gel eluting with 4:1 to 1:1 EtOAc/Hexanes to afford N-BOC-4-amino-L-phenylalanine, ethyl<br>
ester (60 g). IH NMR (400 MHz, CDCls) 5 6.90 (d, 2H), 6.63 (d, 2H), 4.20-4.50 (m,lH), 4.14 (q, 2H),<br>
3.76-3.00 (m, 2H), 1.36 (s, 9H), 1.20 (t, 3H).<br>
Step D: A nitrogen flushed 500 mL round bottom flask was charged with 3,5-dichloroisonicotinic acid<br>
(46.5 g, 0.24 mol), CH2C12 (150 mL), DMF (0.5 mL), and thionyl chloride (20 mL, 33.9 g 0.28 mol).<br>
After the slurry was refluxed for 5 h, additional thionyl chloride (5 mL, 0.70 mol) and CH2C12 (100 mL)<br>
were added, and the reaction mixture was refluxed for additional 45 min and concentrated, and the<br>
residue was azeotroped with toluene to give the crude acyl chloride, which was used immediately. The<br>
crude acyl chloride was dissolved in CH2C12 (150 mL) and added to the compound of Step C (60 g, 0.20<br>
mol) and 4-methylmorpholine (44 mL, 0.40 mol) in CH2C12 (400 mL) at 0Â°C over 5 min. After stirring<br>
at 0Â°C for 1 h, the reaction was quenched with dilute aqueous NaHCO3_ The organic layer was separated<br>
and the aqueous layer was extracted with CH2C12 (500 mL). The organic layers were combined, dried<br>
over anhydrous MgSO4 and concentrated in vacua, and the residue was purified by flash column<br>
chromatography on silica gel eluting with 4:1 to 3:2 EtOAc/hexanes to afford N-BOC-4-((3',5'-dichloroisonicotinoyl)<br>
amino)-L-phenylalanine, ethyl ester (95 g). IH NMR (400 MHz, CD^OD) 5 8.60 (s, 2H),<br>
7.54 (d, 2H), 7.20 (d, 2H), 4.20-4.36 (m, IH), 4.10 (q, 2H), 3.02-3.12 (m, IH), 2.82-2.92 (m, IH),<br>
1.34/1.30 (s,9H),1.20(t,3H).<br>
Step E: A solution of the compound of Step D (95 g, 0.197 mol) in EtOAc (1.2 L) was treated with a<br>
stream of hydrogen chloride gas over 2 h at rt. The resulting yellow suspension was diluted with hexanes<br>
(250 mL), cooled to 0Â°C and filtered. The cake was washed with hexanes and dried in vacua to afford<br>
the title compound as a yellow solid (80 g). IH NMR (400 MHz, CDsOD) 5 8.64 (s, 2H), 7.66 (d, 2H),<br>
7.30 (d, 2H), 4.28 (dd, IH), 4.25 (q, 2H), 3.20 (q, 2H), 1.26 (t, 3H).<br>
EXAMPLE 1<br>
isonicotinovnamino]-(L)-phenylalanine ethyl ester<br>
Step 1: Methyl (2iS',4iSVl-[(3-cvanophenyl')sulfonyl]-4-hydroxypyrrolidine-2-carboxylate.<br>
To a solution of cw-4-hydroxy-Z-proline methyl ester (10.0 g, 68.8 mmol), triethylamine<br>
(13.9 g, 138 mmol), and CH2C12 (200 mL) was added 3-cyanobenzene-l-sulfonyl chloride (13.9 g, 68.8<br>
mmol). After 1 h, the reaction was partitioned between saturated aqueous NaHCC3 (75 mL) and CH2C12<br>
(100 mL). The layers were separated and the aqueous layer was extracted with CH2C12 (3 x 75 mL). The<br>
combined organic layers were dried (MgSO4), filtered, and concentrated. The residue was purified on<br>
silica gel (1:99 - 30:70 ethyl acetate-hexanes) to afford the title compound as a colorless crystalline<br>
solid: 'HNMRtSOOMHz, CDC13) 8 8.19-8.18 (m, IH), 8.13-8.11 (m, IH), 7.89-7.85 (m, IH), 7.69-7.65<br>
(t, IH), 4.52-4.50 (m, IH), 4.44-4.43 (m, IH), 3.67 (s, 3H), 3.52 (dd, IH), 3.47-3.41 (m, IH), 3.1 (d, IH),<br>
2.33-2.27 (m, IH), 2.20-2.17 (m, IH); LRMS (ESI) mlz 311 (311 calcd for GI 3^4^058, M+H).<br>
-17-<br>
Step 2: Methyl (Zy. Vl-fG-cyanophenvDsulfonvlM-OJ-difluoropiperidin-l-ynpvrrolidine-Zcarboxvlate.<br>
To a solution of the compound of Step 1 (19.6 g, 63.2 mmol), diisopropylethylamine<br>
(16.5 g, 127 mmol), and CH2C12 (200 mL) was added trifluoromethanesulfonic anhydride (17.8 g, 63.2<br>
mmol) via syringe pump at -60 Â°C over 30 minutes. The resulting solution was then warmed to -20 Â°C<br>
over 1.5 h, whereupon diisopropylethylamine (5.5 g, 42.5 mmol) was added followed by 3,3-difluoropiperidine<br>
hydrochloride (6.67 g, 42.5 mmol). The mixture was then slowly warmed to rt over 5 h. After<br>
12 h at it, the reaction was partitioned between H2O (150 mL) and CH2C12 (100 mL). The layers were<br>
separated and the aqueous layer was extracted with CH2C12 (3 x 100 mL). The combined organic layers<br>
were dried (MgSO4), filtered, and concentrated. The residue was purified on silica gel (1:99 - 99:1<br>
ethyl acetate-hexanes) to afford the title compound as a colorless foam: !H NMR (500 MHz, CDC13) S<br>
8.16 (s, 1H), 8.10 (d, 1H), 7.88 (d, 1H), 7.68 (t, 1H), 4.48-4.59 (m, 1H), 3.73 (s, 3H), 3.68-3.65 (m, 1H),<br>
3.22-3.17 (m, 2H), 2.64 (br q, 1H), 2.51 (br q, 1H), 2.42-2.41 (m, 2H), 2.23-2.20 (m, 1H), 2.13-2.04 (m,<br>
1H), 1.90-1.82 (m, 2H), 1.74-1.72 (m, 2H); LRMS (BSD mlz 414 (414 calcd for CisH2lF2N3O4S,<br>
M+H).<br>
Step 3: -W-r(3-Cvanobenzene'sulfonvn-4fj;V[3.3-difluoropiperdinvn-fLVprolvl-4-rf3'.5'-dichloro<br>
isonicotinovDamino]-(L)-phenylalanine ethyl ester.<br>
LiOH monohydrate (1.54 g, 64.4 mmol) was added to a solution of the compound of<br>
Step 2 (13.3 g, 32.2 mmol), CHaCN (80 mL), and IfeO (40 mL) at rt After 2 h, a H2O solution of HC1<br>
(65 mL, 65 mmol, 1 N) was added and the solution was partitioned between ethyl acetate. The layers<br>
were separated and the aqueous layer was extracted with ethyl acetate (6 x 100 mL). The combined<br>
organic layers were dried (MgSC4), filtered, and concentrated. The resulting residue was used in the<br>
next step without further purification: LRMS (ESI) mlz 400 (400 calcd for Ci7Hi9F2N3O4S, M+H).<br>
Triethylamine (16.4 g, 161 mmol) was added dropwise to a mixture of residue from<br>
above (12.8 g, 32.2 mmol), compound of Reference Example 1 (13.4 g, 32.2 mmol), N-(3-dimethylaminopropyl)-<br>
N'-ethylcarbodiimide hydrochloride (12.3 g, 64.4 mmol), 1-hydroxybenzotriazole hydrate<br>
(8.7 g, 64.4 mmol), and DMF (140 mL) at rt. After 12 h, the reaction was partitioned between H^O (500<br>
mL) and ethyl acetate (200 mL). The layers were separated and the aqueous layer was extracted with<br>
ethyl acetate (3 x 200 mL). The combined organic layers were washed with brine (1 x 150 mL), dried<br>
(MgSO4), filtered, and concentrated. The residue was purified on silica gel (5:95 -Â» 99:1 ethyl acetatehexanes)<br>
to afford the title compound as a colorless foam: !H NMR (500 MHz, CDsOD) 8 8.66 (s, 2H),<br>
8.22-8.21 (m, 1H), 8.06-8.03 (m, 2H), 7.77 (t, 1H), 7.67-7.64 (m, 2H), 7.35-7.32 (m, 2H), 4.74-4.71 (m,<br>
1H), 4.36-4.34 (m, 1H), 4.22 (q, 2H), 3.70-3.67 (m, 1H), 3.25-3.22 (dd, 1H), 3.11-2.95 (m, 3H), 2.64-2.48<br>
(m ,2H), 2.40-2.38 (m, 2H), 2.10-2.04 (m, 1H), 1.9-1.65 (m, SH), 1.28 (t, 3H); LRMS (ESI) mlz 763 (763<br>
calcd for C34H34CI2F2N6O6S, M+H).<br>
EXAMPLE 2<br>
N-{N-[(3-Cvanobenzene)sulfonvl]-4(R)[3.3-difluoropiperdinvn-(L)-prolvn-4-[(3'.5'-dichloroisonicotinovDamiriol-<br>
fLVphenylalanine<br>
Lithium hydroxide monohydrate (126 mg, 5,24 mmol) was added to a solution of the<br>
compound of Example 1 (1.90 g, 2.62 mmol), CHsCN (13 mL), and H2O (7 mL) at rt. After 2 h, a<br>
solution of HC1 (5.3 mL, 5.3 mmol, 1 N) was added and the solution was partitioned between ethyl<br>
acetate (20 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (6 x<br>
20 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated. The residue was<br>
purified on silica gel (1:99 -20:80 methanol-CH2Cl2) to afford the title compound as a colorless foam:<br>
'H NMR (500 MHz, CDsOD) 6 8.65 (s, 2H), 8.22 (s, IH), 8.04 (d, 2H), 7.76 (t, IH), 7.65 (d, 2H), 7.35<br>
(d, 2H), 4.73-4.70 (m, IH), 4.38-4.35 (m, IH), 3.71-3.68 (m, IH), 3.33-3.29 (dd, IH), 3.11-2.95 (m, 3H),<br>
2.65-2.50 (m, IH), 2.40-2.39 (m, 2H), 2.11-2.10 (m, IH), 1.86-1.60 (in, 5H); LRMS (ESI) mlz 735 (735<br>
calcd for C32H3QC12F2N6O6S, M+H).<br>
EXAMPLES<br>
JV-[3-Cvanobenzene)sulfonvn-4fV[3.3-difluoroazetidin-l-vn-(LVprolvn-4-rr3'.5'-dichloroisonicotinovDaminoMLVphenvlalanine<br>
ethyl ester<br>
CO2Et<br>
Utilizing the general procedure outlined in Example 1, Steps 2-3, 3,3-difluoropiperidine<br>
hydrochloride was exchanged for 3,3-difluoroazetidine hydrochloride to afford the title compound after<br>
preparative reverse phase HPLC purification (Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm,<br>
20:80 - 100:0 acetonitrile-water 0.01% TFA) colorless foam: 'HNMR (500 MHz, CDjOD) 8 8.65 (s,<br>
2H), 8.21 (s, IH), 8.04-8.01 (m, 2H), 7.75 (t, IH), 7.65 (app d, 2H), 7.36 (app d, 2H), 4.74-4.72 (m, IH),<br>
4.34 (t, IH), 4.20 (q, 2H), 3.61-3.44 (m, 5H), 3.33-3.10 (m, 4H), 2.05-2.01 (m, IH), 1.92-1.88 (m, IH),<br>
1.26 (t, 3H); LRMS (ESI) mlz 735 (735 calcd for C32H3lCl2F2N6O6S, M+H).<br>
EXAMPLE 4<br>
A-W-[(3-Cvanobenzene' sulfonvl1-4(/?V[3.3-difluoroazetidin-l-vl1-nL)-prolvn-4-r(3'.5'-dichloroisonicotinoyl)<br>
amino]-(LVphenvlalanine<br>
Utilizing the general procedure outlined in Example 2, the compound of Example 3 was<br>
converted to the title compound after preparative reverse phase HPLC purification (Phenomenex Synergi<br>
4u Max-RP 80A, 100 x 20.2 mm, 20:80 - 100:0 acetonitrile-water 0.01% TFA) colorless foam: 'H<br>
NMR (500 MHz, CDsOD) 5 8.65 (s, 2H), 8.20 (s, IH), 8.04-7.97 (m, 2H), 7.74(t, IH), 7.65 (d, 2H), 7.39<br>
(d, 2H), 4.74-4.71 (m, IH), 4.37 (t, IH), 3.68-3.62 (m, 2H), 3.55-3.48 (m, 3H), 3.32-3.20 (m, 4H), 3.11-<br>
3.04 (m, IH), 2.07-1.91 (m, 2H); LRMS (ESI) mlz 707 (707 calcd for C3QH27C12F2N6O6S, M+H).<br>
EXAMPLES<br>
JV-(7/-rr3-Cvanobenzene)sulfonvn-4(-r3.3-difluoropvrrolidine1-('LVprolvn-4-r(3'.5&gt;-dichloroisonicotinovnaminol-<br>
rD-phenvlalanine ethyl ester<br>
Utilizing the general procedure outlined in Example 1, Steps 2-3, 3,3-difluoropiperidine<br>
hydrochloride was exchanged for 3,3-difluoropyrrolidine hydrochloride to afford the title compound as a<br>
colorless foam: ]H NMR (500 MHz, CDaOD) 5 8.64 (s, 2H), 8.25-8.24 (m, IH), 8.10-8.07 (m, IH), 8.04-<br>
8.02 (m, IH), 7.77 (t, IH), 7.67-7.64 (m, 2H), 7.35-7.32 (m, 2H), 4.78-4.75 (m, IH), 4.34-4.31 (m, IH),<br>
4.21 (q, 2H), 3.61-3.59 (m, IH), 3.29-3.24 (m, 2H), 3.11 (m, IH), 2.89-2.80 (m, 3H), 2.60-2.58 (m, 2H),<br>
2.04-1.95 (m, 4H), 1.28 (t, 3H); LRMS (ESI) mfe 749 (749 calcd for C33H32C12F2N6O6S, M+H).<br>
EXAMPLE 6<br>
W-[f3-Cvanornzene^sulfonvl]-4(V[3.3-difluoropvrrolidineHLVprolvn-4-r(35'-dichloroisonicotinoyl')<br>
amino]-fLVphenylalanine<br>
Utilizing the general procedure outlined in Example 2, the compound of Example 5 was<br>
converted to the title compound as a white solid: JH NMR (500 MHz, CDsOD) 5 8.52 (s, 2H), 8.13 (m,<br>
IH), 7.98-7.97 (m, IH), 7.90-7.88 (m, IH), 7.65 (t, IH), 7.50 (d, 2H), 7.24 (d, 2H), 4.54 (m, IH), 4.20-<br>
4.17 (m, IH), 3.47-3.44 (m, IH), 3.22-3.20 (m, IH), 3.13-3.10(m, IH), 3.04-3.02 (m, IH), 2.73-2.67 (m,<br>
3H), 2.50-2.47 (m, 2H), 1.95-1.82 (m, 4H); LRMS (ESI) TM/Z 721 (721 calcd for<br>
M+H).<br>
NEXAMPLE?<br>
3-difluoropyrrolidine]-(L)-prolvl } -4-[G ' .5 '-dichloroisonicotinoynaminol-<br>
fLVphenvlalanine methyl ester<br>
To a solution of the compound of Example 6 (50 mg, 0.07 mmol) in anhydrous methanol<br>
(1 mL) was added trimethylsilyldiazomethane (2 M in ether) at 0Â°C until a yellow color persisted. After<br>
stirring at room temperature for 15 min, the mixture was concentrated to dryness to afford the title<br>
compound as a colorless foam: ]HNMR (500 MHz, CD3OD) 5 8.64 (s, 2H), 8.21 (m, 1H), 8.06-8.04 (m,<br>
1H), 8.02-8.00 (m, 1H), 7.77 (t, 1H), 7.63-7.61 (m, 2H), 7.23-7.21 (m, 2H), 4.76 (m, 1H), 4.30-4.29 (m,<br>
1H), 3.74 (a, 3H), 3.58-3.57 (m, 1H), 3.28-3.24 (m, 2H), 3.10-3.08 (m, 1H), 2.87-57 (m ,5H), 2.04-1.92<br>
(m, 4H); LRMS (ESI) m/z 735 (735 calcd for C32H30C12F2N6O6S, M+H).<br>
EXAMPLES<br>
tsonicotinoynamino]-(L)-phenvlalanme ethyl ester<br>
Utilizing the general procedure outlined in Example 1, c;s-4-hydroxy-I-proline methyl<br>
ester was exchanged for fraras-4-hydroxy-i-proline methyl ester to afford the title compound as a<br>
colorless foam: LRMS (ESI) m/z 749 (749 calcd for C33H33C12F2N6O6S, M+H).<br>
EXAMPLE 9<br>
7V-(A-rf3-Cvanobenzene^sulfonvn-4(-[3.3-difluoropvrrolidine1-(LVprolvl}-4-[(3'.5'-dichloroisonicotinoyl)<br>
amino]-(LVph.envlalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound was<br>
obtained from the compound of Example 8 after preparative reverse phase HPLC purification<br>
(Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm, 20:80 H 100:0 acetonitrile-water 0.01% TFA)<br>
colorless foam: 'HNMR(500 MHz, CDsOD) 8 8.65 (s, 2H), 8.24 (s, IH), 8.09-8.03 (m, 2H), 7.77 (t,<br>
IH), 7.36 (d, 2H), 7.37 (d, 2H), 4.73-4.69 (m, IH), 4.41-4.38 (m, IH), 3.75-3.40 (m, 7H), 3.30-3.25 (m,<br>
2H), 3.10 (dd, IH), 2.55-2.48 (m, 3H), 2.28-2.21 (m, IH); LRMS (ESI) m/z 721 (721 calcd for<br>
C3 1H29C12F2N606S, M+H).<br>
EXAMPLE 10<br>
A-(-[(3-Cvanobenzene')sulfonvn-4Vr4.4-difluoropiperdinvl1-rLVprolvn-4-[G'.5'-dichloroisonicotinoyl)<br>
aim'no1-(LVphenylalanine ethyl ester<br>
CO2Et<br>
O Cl<br>
Utilizing the general procedure outlined in Example 1, Steps 2-3, 3,3-difluoropiperidine<br>
hydrochloride was exchanged for 4,4-difluoropiperidine hydrochloride to afford the title compound as a<br>
colorless foam: JH NMR (500 MHz, CDCls) 5 8.56 (s, 2H), 8.13 (s, IH), 8.06 (d, IH), 7.91 (d, IH) 7.70<br>
(t, IH), 7.64 (br s, IH), 7.54 (d, 2H), 7.20 (d, 2H), 7.06 (br d, IH), 4.83-4.81 (m, IH), 4.25 (q, 2H), 4.17<br>
(d, IH), 3.64-3.61 (m, IH), 3.26 (dd, IH), 3.10 (dd, IH), 2.90 (t, IH), 2.80-2.70 (m, IH), 2.48-2.39 (m,<br>
4H), 2.31-2.25 (dd, IH), 1.94-1.83 (m, 4H), 1.59-1.51 (m, IH), 1.32 (t, 3H); LRMS (ESI) m/z 763 (763<br>
calcd for C34H35C12F2N6O6S, M+H).<br>
EXAMPLE 1 1<br>
AT-(Ar-r(3-Cvanobenzene'sulfonvl1-4(V[4.4-difluoropiperdinvl1-(LVproIvn-4-r(3\5J-dichloroisonicotinovDaniinol-<br>
fLVphenylalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound was obtained<br>
from the compound of Example 10 as a colorless team: !H NMR (500 MHz, CDsOD) 8 8.64 s, 2H),<br>
8.23 (s, IH), S.04-8.02 (m, 2H), 7.75 (t, IH), 7.63 (d, 2H), 7.34 (d, 2H), 4.70-4.67 (m, IH), 4.40 (d, IH),<br>
3.73-3.72 (m, IH), 3.30 (dd, IH), 3.28-3.05 (m, 3H), 2.58-2.54 (m, 4H), 2.13-2.12 (m, IH), 1.95-1.80 (m,<br>
5H); LRMS (ESI) jjj/z 735 (735 calcd for C32H3lCl2F2N6O6S, M+H).<br>
EXAMPLE 12<br>
jy-(A-f(3-Cyaaobenzene')sulfonyl]-4fJ?V[3.3-difluQropiperdinyl]-(L)-proIyU-4-[(;3?.5'-dichloroisQnicotinoyl')<br>
aminol-('LVphenylalanine-2-methoxyethyl ester<br>
Potassium carbonate (33.0 mg, 0.24 mmol) was added to a solution of the compound of<br>
Example 2 (60.0 mg, 0.08 mmol), l-bromo-2-methoxyethane (22.0 mg, 0.16 mmol), and DMF (1.5 mL).<br>
After 24 h, trifluoroacetic acid (45.6 mg, 0.40 mmol) was added and the mixture was directly purified by<br>
preparative reverse phase HPLC purification (Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm,<br>
20:80 - 100:0 acetonitrile-water 0.01% TFA) to afford the title compound as a colorless foam: 'H NMR<br>
(500 MHz, CDsOD) 5 8.64 (s, 2H), 8.49 (br d, IH), 8.17 (s, IH), 8.02 (d, IH), 7.93 (d, IH), 7.71 (t, IH),<br>
7.65 (d, 2H), 7.35 (d, 2H), 4.68-4.60 (m, IH), 4.49 (d, IH), 4.30-4.20 (m, 2H), 3.82 (dd, IH), 3.67-3.60<br>
(m, 3H), 3.34 (s, 3H), 3.32-3.30 (m, IH), 3.28 (dd, IH), 3.20-3.13 (m, IH), 3.03-3.10 (dd, IH), 2.95-2.90<br>
(m, 2H), 2.27 (dd, IH), 2.08-1.96 (m, 3H), 1.90-1.80 (m, 2H); LRMS (ESI) m/z 793 (793 calcd for<br>
, M+H).<br>
EXAMPLE 13<br>
(rG-Cvanobenzenesulfonvl1-4(J?V|'3.3-difluoropiperdinvl1-(L)-prolvn-4-rr3'.5'-dichloroisonicotinoyDaminoJ-<br>
rLVphenylalanine-choline ester<br>
Utilizing the general procedure outlined in Example 12, l-bromo-2-methoxyethane was<br>
exchanged for 2-bromo-N, W.Af-trimethylethanarninium bromide to afford the title compound as a<br>
colorless foam: 'HNMR (500 MHz, CDOD) 5 8.64 (s, 2H), 8.60 (br d, IH), 8.23 (s, IH), 8.09 (d, IH),<br>
8.05 (d, IH), 7.79 (t, IH), 7.62 (d, 2H), 7.34 (d, 2H), 4.75-4.70 (m, IH), 4.65-4.52 (m, 2H), 4.33-4.31 (m,<br>
IH), 3.80-3.70 (m, IH), 3.78-3.66 (m, 2H), 3.30 (dd, IH), 3.16-3.10 (m, 13H), 2.80-2.68 (m, 2H), 2.54-<br>
2.52 (m, 2H), 1.91-1.80 (m, 4H), 1.65-1.70 (m, 2H); LRMS (ESI) m/z 820 (820 calcd for<br>
EXAMPLE 14<br>
Ar-W-[(3-Cvanobenzenesulfonvl1-4(J?Vr3.3-difluoropvrrolidine1-rLVprolvn-4-fG;.5'-dichloroisonicotinovDamino1L-phenvlalanine choline ester<br>
If \\ ,N<br>
Utilizing the general procedure outlined in Example 12, using the compound of Example<br>
6 and 2-bromo-N,N,N-trimethylethanaminium bromide, the title compound was obtained after<br>
preparative reverse phase HPLC purification (Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm,<br>
20:80-^100:0 acetonitrile-water 0.01% TFA) as a colorless foam: IH NMR (500 MHz, CD3OD) 8 8.65<br>
(s, 2H), 8.28-8.25 (m, IH), 8.14-8.12 (m, IH), 8.06-8.04 (m, IH), 7.80-7.77 (t, IH), 7.64-7.60 (m, 2H),<br>
7.34-7.32 (m, 2H), 4.79-4.75 (m, 1H), 4.65-4.50 (m, 2H), 4.24-4.22 (m, 1H), 3.70-3.61 (m, 3H), 3.57-<br>
3.14 (m, 12H), 2.87-2.55 (m, 5H), 2.10-1.95 (m,3H), 1.80-1.78 (m, 1H); LRMS (ESI) m/z 806 (806 calcd<br>
for C36H40C12F2N7O6S+, M+).<br>
EXAMPLE 15<br>
N-lN-[(3, 5-Difluorobenzene)sulfonvl]-4-[3.3-difluoropvrrolidine1-(LVprolyn-4-[(3',5'-dichloroisonicotinoyDaminoj-<br>
CD-phenvlalanine ethyl ester<br>
Utilizing the general procedure outlined in Example 1, Steps 1-3, 3-cyanobenzene-lsulfonyl<br>
chloride was exchanged for 3,5-difluorobenzene-l-sulfonyl chloride to afford title compound as<br>
a colorless foam: 'H NMR (500 MHz, CDsOD) 5 8.62 (s, 2H), 7.63-7.61 (m, 2H), 7.48-7.45 (m, 2H),<br>
7.36-7.29 (m, 3H), 4.73-4.70 (m, 1H), 4.32-4.30 (m, 1H), 4.22-4.17 (q, 2H), 3.72-3.70 (m, 1H), 3.23-<br>
3.22 (m, 1H), 3.10-3.04 (m, 2H), 3.00-2.94 (m, 1H), 2.61-2.50 (m, 2H), 2.38 (m, 2H), 2.10-2.05 (m, 1H),<br>
1.83-1.77 (m, 3H), 1.65 (m, 2H), 1.28-1.25 (t, 3H); LRMS (ESI) z/z 774 (774 calcd for<br>
, M+H).<br>
EXAMPLE 16<br>
N-iN-\(3. 5-Difluorobenzene')sulfonvl]-4f/gVr3.3-difluoropyrrolidine1-rLVprolvn-4-r(3'.5J-dichloroisonicotinovnamino] L)-phenylalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound was obtained<br>
from the compound of Example 15 after preparative reverse phase HPLC purification (Phenomenex<br>
Synergi 4u Max-RP 80A, 100 x 20.2 mm, 20:80 -Â» 100:0 acetonitrile-water 0.01% TFA) as a white<br>
solid: 'H NMR (500 MHz, CDsOD) 8 8.64 (s, 2H), 7.63-7.62 (d, 2H), 7.43-7.31 (m, 5H), 4.64-4.60 (m,<br>
2H), 4.20-4.14 (m, 1H), 4.00-3.96 (m, 1H), 3.72-3.56 (m, 3H),3.46-3.01 (m, 4H), 2.50-2.06 (m, 6H);<br>
LRMS (ESI) m/s 746 (746 calcd for C3iH29Cl2F4N5O6S, M+H).<br>
EXAMPLE 17<br>
JÂ¥-W-rf3-Cvanobenzenesulfonvn-4-r2r-ftrifluoromethvl)pvrrolidinel-('LVprolvU-4-rr3'.57-<br>
dichloroisonicotinoyl)ammo]-rLVphenvlalanine ethyl ester<br>
R F Â°VoEt<br>
Utilizing the general procedure outlined in Example 1, Steps 2-3, 3,3-difluoropiperidine<br>
hydrochloride was exchanged for 2(5)-(trifluoromethyl)pyrrolidine to afford the title compound as a<br>
white solid: }H NMR (500 MHz, CDsOD) 5 8.64 (s, 2H), 8. 17 (m, IH), 8.03-8.00 (m, 2H), 7.77-7.74 (t,<br>
IH), 7.63-7.62 (d, 2H), 7.32-7.30 (d, 2H), 4.72-4.70 (m, IH), 4.35-4.32 (m, IH), 4.22-4.18 (q, 2H), 3.<br>
3.60 (m, IH), 3.48-3.42 (m, IH), 3.35-3.30 (m, 2H), 3.09-3.01 (m, 2H), 2.88-2.73 (m, IH), 2.52-2.44 (m,<br>
IH), 2.00-1.80 (m, 4H), 1.76-1.74 (m, 2H), 1.28-1.25 (t, 3H); LRMS (ESI) mlz 781 (781 calcd for<br>
C34H33C12F3N606S, M+H).<br>
EXAMPLE 18<br>
dichloroisonicotinoynaminoj-fLVphenylalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound was obtained<br>
from the compound of Example 17 as an off-white solid: H NMR (500 MHz, CD3OD) Â§ 8.65 (s, 2H),<br>
8.21 (s, IH), 8.04-8.02 (m, 2H), 7.79-7.76 (t, IH), 7.66-7.64 (d, 2H), 7.36-7.34 (d, 2H), 4.74-4.72 (m,<br>
IH), 4.39-4.37 (m, IH), 3.64-3.61 (m, IH), 3.53-3.45 (m, IH), 3.33-3.29 (m, 2H), 3.11-3.05 (m, 2H),<br>
2.90-2.89 (m, IH), 2.53-2.51 (m, IH), 2.06-1.78 (m, 6H); LRMS (ESI) mlz 753 (753 calcd for<br>
, M+H).<br>
EXAMPLE 19<br>
y-(7Vr(3-Cyanobenzene)sulfonyl1-4fJ?)-r2-('trifluoromethvnpvrrolidine]-(LVprolyU-4-[('3'.5'-dichloroisonicotinovl)<br>
amino]-(LVphenylalanine ethyl ester<br>
Utilizing the general procedure outlined in Example 1, Steps 2-3, 3,3-difluoropiperidine<br>
hydrochloride was exchanged for 2-(trifluoromethyl)pyrrolidine to afford the title compound, a white<br>
solid, as a mixture of diastereomers: 'H NMR (500 MHz, CDsOD) 6 8.62 (s, 2H), 8.22-8.18 (m, IH),<br>
8.05-8.00 (m, 2H), 7.77-7.74 (m, IH), 7.63-7.62 (in, 2H), 7.32-7.30 (m, 2H), 4.73-4.70 (m, IH), 4. 4.33 (m, IH), 4.22-4.18 (m, 2H), 3.62-3.60 (m, IH), 3.48-3.22 (m, 3H), 3.09-3.04 (m, 2H), 2.90-2.91 (m,<br>
IH), 2.52-2.44 (m, IH), 2.00-1.80 (m, 4H), 1.76-1.74 (m, 2H), 1.28-1.25 (m, 3H); LRMS (ESI) m/z 781<br>
(781 calcd for C34H33C12F3N6O6S, M+H).<br>
EXAMPLE 20<br>
A-W-r(3-Cvanobenzenesulfonvn-4(RVr2-(trifluoromethvnpvrrolidine1-rLVprolvl)-4-[('3'.5'-dichloroisonicotinoyl')<br>
amino]-(L)-phenvlalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound (as a mixture<br>
of diastereomers) was obtained from the compound of Example 19 as an off-white solid,: JH NMR (500<br>
MHz, CD3OD) 8 8.63 (s, 2H), 8.21-8.19 (m, IH), 8.02-8.00 (m, 2H), 7.76-7.71 (m, IH), 7.63-7.61 (m,<br>
2H), 7.34-7.31 (d, 2H), 4.71-4.69 (m, IH), 4.36-4.34 (m, IH), 3.61-3.58 (m, IH), 3.34-3.27 (m, 3H),<br>
3.09-3.02(m, 2H), 2.89-2.87 (m, 1H),2.51-2.50 (m, IH), 2.03-1.75 (m, 6H); LRMS (ESI) T/Z 753 (753<br>
calcd for C32H3QC12F3N6O6S, M+H).<br>
EXAMPLE 21<br>
jsonicotinovnaminol-fLVphenvlalanine ethvl ester<br>
Utilizing the general procedure outlined in Example 1, Steps 2-3, 3,3-difluoropiperidine<br>
hydrochloride was exchanged for (3S)-3-fluoropyrrolidine hydrochloride to give after preparative reverse<br>
phase HPLC purification (Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm, 10:90 80:20<br>
acetonitrile-water 0.01% TFA), the title compound as a white solid: !H NMR (500 MHz, CDsOD) 8 8.62<br>
(s, 2H), 8.16 (s, 1H), 8.09-8.07 (m, 1H), 7.96-7.95 (m, 1H), 7.77-7.71 (m, 2H), 7.56-7.54 (m, 2H), 7. 7.30 (m, 1H), 5.30-5.25 (m, 1H), 4.89-4.87 (m, 1H), 4.31 (q, 2H), 4.23 (d, 1H), 3.85 (t, 1H), 3.55-3.46<br>
(m, 2H), 3.40-3.37 (dd, 2H), 3.20-3.15 (m ,2H), 3.04-3.00 (m, 1H), 2.54-2.50 (m, 1H), 2.35-2.30 (m, 2H),<br>
2.05-1.98 (m, 1H), 1.90-1.85 (m, 1H), 1.39-1.34 (t, 3H); LRMS (ESI) m/z 732 (732 calcd for<br>
C33H34C12FN606S, M+H).<br>
EXAMPLE 22<br>
N- W-rr3-(anobenzene)sulfbnvll-4(7?V[Y 3.SV3-fluoropvrrolidine1-(LVprolvl) -4-[C3 \5 '-dichloroisonicotinoyl)<br>
amino]-fLVphenvlalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound was obtained<br>
from compound of Example 21 after preparative reverse phase HPLC purification (Phenomenex Synergi<br>
4u Max-RP 80A, 100 x 20.2 mm, 0:100 80:20 acetonitrile-water 0.01% TFA) as a white solid: 1H<br>
NMR (500 MHz, CDsOD) 8 8.63 (s, 2H), 8.49-8.48 (m, 1H), 8.11 (s, 1H), 8.00-7.99 (m, 1H), 7.82-7.80<br>
(m, 1H), 7.68-7.63 (m, 3H), 7.38-7.36 (m, 2H), 5.47-5.36 (m, 1H), 4.63-4.58 (m, 2H), 4.09-4.07 (m, 1H),<br>
3.94-3.91 (m, 1H), 3.80-3.40 (m, 5H), 3.31-3.26 (m, 1H), 3.04-3.00 (m, 1H), 2.44-2.25 (m, 4H), LRMS<br>
(ESI) mlz 704 (704 calcd for CsiHsoC^FNgOgS, M+H).<br>
EXAMPLE 23<br>
A^-W-[(3-Cvanobeiizene'lsalfonvl]-4(;j?Vfr37?V3-fluoropvrrolidine]-(L)-prolvll-4-[(3'.5'-dichloroisonicotinovDaminol-<br>
CLVphenylalanine ethyl ester<br>
Utilizing the general procedure outlined in Example 1 Steps 2-3, 3,3-difluoropiperidine<br>
hydrochloride was exchanged for (3/?)-3-fluoropyrrolidine hydrochloride to give after preparative reverse<br>
phase HPLC purification (Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm, 10:90 80:20<br>
acetonitrile-water 0.01% TFA), to afford the title compound as a white solid: 1R NMR (500 MHz,<br>
CDsOD) 8 8.65 (s, 2H), 8.60-8.59 (m, IH), 8.16 (m, IH), 8.04-8.03 (m, IH), 7.90-7.89 (m, IH), 7.73-<br>
7.66 (m, 3H), 7.38-7.36 (m, 2H), 5.49-5.38 (m, IH), 4.64-4.62 (m, 2H), 4.19 (q, 2H), 4.10-4.00 (m, IH),<br>
3.93-3.89 (m, IH), 3.80-3.70 (m, IH), 3.65-3.35 (m, 3H), 3.27-3.04 (m,3H), 2.40-2.29 (m, 4H), 1.33-1.26<br>
(m, 3H), LRMS (ESI) m/z 732 (732 calcd for C33H34C12FN6O6S, M+H).<br>
EXAMPLE 24<br>
Ar-W-f(3-Cvanobenzene)sulfonvl]-4(/;)4GJ?)-3-fluoropvrrolidinel-fLVprolvl)-4-r(3'.5'-dichloroisonicotinovl)<br>
amino]-(LVphenylalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound was obtained<br>
from compound of Example 23 after preparative reverse phase HPLC purification (Phenomenex Synergi<br>
4u Max-RP 80A, 100 x 20.2 mm, 0:100 - 80:20 acetonitrile-water 0.01% TFA) as a white solid: 1U<br>
NMR (500 MHz, CD3OD) 8 8.64 (s, 2H), 8.51-8.48 (m, IH), 8.14 (s, IH), 8.02-8.00 (m, IH), 7.85-7.83<br>
(m, IH), 7.71-7,67 (m, 3H), 7.40-7.39 (m, 2H), 5.50-5.40 (m, IH), 4.67-4.60 (m, 2H), 4.12-3.80 (m, IH),<br>
3.92-3.79 (m, 2H), 3.70-3.45 (m, 4H), 3.34-3.29 (m, 3H), 3.06-3.02 (m, IH), 2.49-2.30 (m, 4H), LRMS<br>
(ESI) mlz 704 (704 calcd for CsiHsoCFNeCS, M+H).<br>
EXAMPLE 25<br>
y-{A-[(3-Cyanobenzene')sulfonvl]-4fJ?Vr4-fluorQpiperdine]-(LVprolvU-4-r(3'.5'-dichloroisonicotiQOvl')-<br>
aminoHLVphenylalanine ethyl ester<br>
Utilizing the general procedure outlined in Example 1 Steps 2-3, 3,3-difluoropiperidine<br>
hydrochloride was exchanged for 4-fluoropiperdine hydrochloride to give the title compound (as a<br>
mixture of diasteromers), after preparative reverse phase HPLC purification (Phenomenex Synergi 4u<br>
Max-RP 80A, 100 x 20.2 mm, 10:90 - 100:0 acetonitrile-water 0.01% TFA), as a white solid: H NMR<br>
(500 MHz, CDsOD) 8 8.63 (s, 2H), 8.58-8.57 (m, IH), 8.15 (s, IH), 8.02-8.00 (m, IH), 7.89-7.87 (m,<br>
IH), 7.71-7.64 (m, 3H), 7.35-7.33 (m, 2H), 4.98-4.81 (m, IH), 4.61-4.58 (m, 2H), 4.17 (q, 2H), 4.06-3.94<br>
(m, 2H), 3.55-3.51 (m, IH), 3.34-3.30 (m, 2H), 3.24-3.02 (m, 3H), 2.42-2.30 (m, 2H), 2.20-2.00 (m ,3H),<br>
1.38-1.35 (m, 2H), 1.24 (t, 3H); LRMS (ESI) /n/z 746 (732 calcd for C34H36C12FN6O6S, M+H).<br>
EXAMPLE 26<br>
A-W-CvanobenzenesulfonyljfJgV-fluoropiperdinej-rLVprolynS'-dichloroisonicotinoylV<br>
aminoWLVphenylalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound (as a mixture<br>
of diastereomers) was obtained from compound of Example 25, after preparative reverse phase HPLC<br>
purification (Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm, 0:100 â80:20 acetonitrile-water<br>
0.01% TFA), as a white solid: 'H NMR (500 MHz, CDsOD) 8 8.62 (s, 2H), 8.48-8.47 (m, IH), 8.12 (s,<br>
IH), 8.00-7.99 (m, IH), 7.83-7.81 (m, IH), 7.68-7.64 (m, 3H), 7.38-7.36 (m, 2H), 4.94-4.82 (m, IH),<br>
4.64-4.57 (m, 2H), 4.04-3.92 (m, 2H), 3.53-3.50 (m, IH), 3.40-3.26 (m, 5H), 3.04-3.00 (m, IH), 2.47-<br>
2.43 (m, IH), 2.47-2.05 (m, 5H), LRMS (ESI) mlz 718 (718 calcd for C32H32C12FN6O6S, M+H).<br>
EXAMPLE 27<br>
AW-[(3-Cvanobenzene)sulfonvl]-3-[3.3-difluoropyrrolidine1-prolvn-4-[(3'.5'-dichloroisonicotinovlV<br>
ammo]-(LVphenvlalanine ethyl ester<br>
Step 1: Synthesis of A^-[(3-Cyanobenzene)sulfonvl]-3-[3.3-difluoropyrrolidine1 methyl ester<br>
To a solution of (3S)-hydroxy-(L)-proline (Acros, 20 g, 0.15 mol) and sodium carbonate<br>
(26 g, 0.25 mol) in 500 mL of water at 0Â°C was added powdered 3-cyanobenzenesulfonyl chloride (25 g,<br>
0.12 mol). After stirring at rt overnight, the reaction mixture was acidified with concentrated HC1<br>
(pH=3), and the product was extracted with EtOAc (3 x 100 mL). The organic extracts were dried<br>
(MgSO4), filtered and concentrated to dryness. The residue was then dissolved in methylene chloride<br>
(100 mL) and MeOH (100 mL), and was added trimethylsilyldiazomethane (2 Mia. ether) at QOC until a<br>
yellow color persisted. After stirring at rt for 15 min, the mixture was concentrated to dryness to give N-<br>
[(3-cyanobenzene)sulfonyl]-3(Â»S)-hydroxy-(L)-proline, methyl ester (31.5 g).<br>
To the above compound (31.5 g, 0.10 mol) in 200 mL of EtOAc at 0Â°C was added TEA<br>
(20 mL, 0.14 mol) and MsCl (9.5 mL, 0.12 mol). After stirring at 0Â°C for 20 min, the reaction was<br>
quenched with 100 mL of aqueous sodium bicarbonate. After stirring for 15 min, the reaction mixture<br>
was partitioned between EtOAc (300mL) and aqueous sodium bicarbonate (200 mL). The organic layer<br>
was separated, washed with brine and concentrated to dryness to give N-[(3-cyanobenzene)sulfonyl]-<br>
3(S)-methanesulfonyloxy-(L)-proline, methyl ester (40 g).<br>
To a solution of the above compound (39.5 g, 0.10 mol) in 300 mL of AcCN was added<br>
TEA (35 mL, 0.25 mol). After heating at 75 Â°C for 4 h, the reaction mixture was cooled to rt and<br>
concentrated. The residue was dissolved in EtOAc (600mL) and washed with 1 N aqueous NaOH and<br>
brine, and concentrated to dryness to give N-[(3-cyanobenzene)sulfonyl]-2,3-dehydroproline, methyl<br>
ester (28 g).<br>
To a suspension of ,/V-[(3-cyanobenzene)sulfonyl]-2,3-dehydroproline methyl ester (0.7<br>
g, 2.4 mmol) in 5 mL of DMF was added 3,3-difluoropyrrolidine hydrochloride salt ( 2 g, 14.0 mmol)<br>
and N,N-diisopropylethylamine (DIPEA) (2.4 mL, 14.0 mmol). After heating at 50 Â°C for 24 h, the<br>
reaction mixture was cooled to room temperature and was concentrated. The residue was purified on<br>
silica gel (1:99 30:70 ethyl acetate-hexanes) to afford A^-[(3-cyanobenzene)sulfonyl]-3-[3,3-<br>
difluoropyrrolidine] methyl ester as a racemic colorless oil mixture: 'H NMR (500 MHz, CD3OD) 5<br>
8.16-8.15 (m, 1H), 8.10-8.08 (m, 1H), 7.88-7.86 (m, 1H), 7.69-7.65 (m, 1H), 4.30 (d, 1H), 3.75 (s, 3H),<br>
3.56-3.47 (m, 2H), 3.14-3.12 (m, 1H), 2.88-2.83 (m, 2H), 2.73-2.70 (m, 2H), 2.19-2.09 (m, 3H), 1.98 (M,<br>
1H); LRMS (ESI) mlz 400 (400 calcd for CiyHipFiNsC^S, M+H).<br>
Utilizing the general procedure outlined in Example 1, Step 3, methyl (2S,4R)-l-[(3-<br>
cyanophenyl)sulfonyl]-4-(3,3-difluoropiperidin-l-yl)pyrrolidine-2-carboxylate was exchanged for N-[(3-<br>
cyanobenzene)sulfonyl]-3-[3,3-difluoropyrrolidine] methyl ester to afford the title compound, a white<br>
solid, as a mixture of diastereomers: 1H NMR (500 MHz, CDsOD) 5 8.64-8.63 (m, 2H), 8.26-8.24 (m,<br>
1H), 8.16-8.09 (m, 1H), 8.02-8.01 (m, 1H), 7.77-7.73 (m, 1H), 7.61-7.58 (m, 2H), 7.31-7.29 (m, 2H),<br>
4.77-4.74 (m, 1H), 4.24-4.21 (m, 2H), 4.10-4.06 (m, 1H), 3.61-3.49 (m, 1H), 3.33-3.26 (m, 2H), 3.09-<br>
3.06 (m, 1H), 2.70-2.51 (m ,5H), 1.94-1.88 (m, 4H), 1.30-1.26 (m, 3H); LRMS (ESI) mlz 749 (749 calcd<br>
for C33H32Cl2F2N606S, M+H).<br>
EXAMPLE 28<br>
AfA-[(3-Cyanobenzene)sulfonyl]-3-[3.3-difluoropyrrolidine1-prolvl-4-fr3'.5'-dichloroisonicotinoylV<br>
amino]-(L)-phenvlalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound (as a mixture<br>
of diastereomers) was obtained from the compound of Example 27 as a white solid, after preparative<br>
reverse phase HPLC purification (Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm, 20:80 100:0<br>
acetonitrile-water 0.01% TFA): JH NMR (500 MHz, CDsOD) 8 8.54-8.53 (d, 2H), 8.16-8.10 (m, 1H),<br>
7.90-8.06-7.90 (m, 2H), 7.67-7.61 (m, 1H), 7.51-7.49 (m, 2H), 7.24-7.22 (m, 2H), 4.68-4.61 (m, 1H),<br>
4.09-4.05 (m, 1H), 3.46-3.18 (m, 2.5H), 3.00-2.91 (m, 1.5H), 2.90-2.64 (m, 5H), 1.95-1.82 (m, 4H);<br>
LRMS (ESI) m/z 721 (721 calcd for â¬31H28C12F2N6O6S, M+H).<br>
EXAMPLE 29<br>
jV-(jV-f(3-Cvanobenzene)sulfonyl]-3-r3.3-difluoropiperdinvn-prolyn-4-[(3\5'-dichloroisonicotinovl)-<br>
aminoj-CLVphenylalanine ethyl ester<br>
Utilizing the general procedure outlined in Example 27, Steps 1-2, 3,3-<br>
difluoropyrrolidine hydrochloride was exchanged for 3,3-difluoropiperidine hydrochloride to afford the<br>
title compound, a white solid, as a mixture of diastereomers: H NMR (500 MHz, CD3OD) 8 8.48-8.47<br>
(d, 2H), 8.07-8.04 (d, IH), 7.98-7.83 (m, 2H), 7.63-7.56 (m, IH), 7.46-7.43 (m, 2H), 7.17-7.12 (m, 2H),<br>
4.57-4.50 (m, IH), 4.10-4.00 (m, 3H), 3.26-3.24 (m, 2H), 3.11-3.09 (m, IH), 2.86-2.70 (m, 2H), 2.30-<br>
2.24 (m, 3H), 2.06-1.90 (m, IH), 1:73-1.60 (m, 4H), 1.45-1.20 (m, 2H), 1.15-1.07 (m, 3H); LRMS (ESI)<br>
mlz 763 (763 calcd for C34H34C12F2N6O6S, M+H).<br>
EXAMPLE 30<br>
JVL{JV-[(3-Cvanobenzene)sulfonvl]-3-r3.3-difluoropiperdinyl]-prolyn-4-[r3'.5'-dichloroisonicotinovlV<br>
amino] -(L Vpheny lalanine<br>
Utilizing the general procedure outlined in Example 2, the title compound (as a mixture<br>
of diastereomers) was obtained from the compound of Example 29 as a white solid: !H NMR (500 MHz,<br>
CD3OD) 8 8.52-8.51 (d, 2H), 8.10-8.09 (d, IH), 8.05-7.93 (dd, IH), 7.90-7.88 (m, IH), 7.66-7.61 (m,<br>
IH), 7.48-7.47 (d, 2H), 7.22-7.21 (d, 2H), 4.55-4.50 (m, IH), 4.03-3.97 (m, IH), 3.43-3.30 (m, IH), 3.25-<br>
3.15 (m, 2H), 3.00-2.98 (m, IH), 2.87-2.76 (m, IH), 2.34-2.26 (m, 3H), 2.06-1.90 (m, IH), 1.89-1.60 (m,<br>
4H), 1.45-1.20 (m, 2H); LRMS (ESI) 7;i/r 735 (735 calcd for C32H3QC12F2N6O6S, M+H).<br>
EXAMPLE 31<br>
JV-W-[(3-Cvanobenzene')sulfonyl]-3-[4,4-difluoropiperdinyl]-prolvU-4-[(3'.5'-dichloroisonicotinovl')-<br>
amino]-(LVphenvlalanine ethyl ester<br>
Utilizing the general procedure outlined in Example 27, Steps 1-2, 3,3-<br>
difluoropyrrolidine hydrochloride was exchanged for 4,4-difluoropiperidine hydrochloride to isolate two<br>
isomers: I and n, of the title compound, as a hydrochloride salt after each isomer was treated with IN<br>
hydrochloride in diethyl ether: Isomer I: 'H NMR (500 MHz, CDsOD) 6 8.65 (s, 2H), 8.05 (s, 1H), 8.01-<br>
8.00 (d, 1H), 7.78-7.76 (d, 1H), 7.69-7.66 (m, 3H), 7.43-7.42 (d, 2H), 4.87-4.84 (m, 1H), 4.63-4.60 (m,<br>
1H), 4.23-4.20 (m, 2H), 4.10-4.09 (m, 1H), 3.85 (m, 1H), 3.71-3.38 (m, 5H), 3.29-3.25 (m, 1H), 3.11-<br>
3.08 (m, 1H), 2.52-2.38 (m, 5H), 2.31-2.25 (m, 1H), 1.30-1.26 (t, 3H); LRMS (ESI) mlz 763 (763 calcd<br>
for C34H34C12F2N6O6S, M+H). Isomer H: ]H NMR (500 MHz, CDsOD) 8 8.67 (s, 2H), 8.22 (s, 1H),<br>
8.15-8.13 (d, 1H), 8.04-8.03 (d, 1H), 7.77-7.74 (t, 1H), 7.60-7.59 (d, 2H), 7.32-7.30 (d, 2H), 4.74-4.71<br>
(m, 1H), 4.36-4.31 (m, 2H), 3.85-3.82 (m, 1H), 3.75-3.72 (m, 1H), 3.52-3.29 (m, 7H), 3.07-3.02 (m, 1H),<br>
2.47-2.30 (m, 6H), 1.35-1.33 (t, 3H); LRMS (ESI) m/z 763 (763 calcd for C34H34C12F2N6O6S, M+H).<br>
EXAMPLE 32<br>
A^-{^-[(3-(&gt;anobenzene)sulfonyl]-3-[4.4-difluoropiperdinyl]-prolyU-4-[(3'.5'-dichloroisonicotinoylV<br>
aminoJ-fLVphenylaJanine<br>
Utilizing the general procedure outlined in Example 2, isomer I and isomer n of the<br>
compound of Example 31 were converted to the title compound, as a hydrochloride salt after each isomer<br>
was treated with IN hydrochloride in diethyl ether. Acid from isomer I ethyl ester: *H NMR (500 MHz,<br>
CD30D) 8 8.41 (s, 2H), 8.05 (s, 1H), 7.89-7.87 (d, 1H), 7.83-7.81 (d, 1H), 7.59-7.54 (t, 1H), 7.36-7.34<br>
(d, 2H), 7.11-7.09 (d, 2H), 4.35-4.32 (m, 1H), 3.85-3.84 (m, 1H), 3.43-3.10 (m, 3H), 2.92-2.88 (m, 1H),<br>
2.77-2.76 (m, 1H), 2.22-2.19 (m, 2H), 2.08-2.06 (m, 2H), 1.54-1.42 (m, 6H); LRMS-(ESI) mlz 735 (735<br>
calcd for C32H3QC12F2N6O6S, M+H). Acid from isomer H ethyl ester: 'H NMR (500 MHz, CD3OD) 8<br>
8.41 (s, 2H), 8.09 (s, 1H), 7.97-7.96 (d, 1H), 7.82-7.81 (d, 1H), 7.58-7.54 (t, 1H), 7.36-7.34 (d, 2H), 7.11-<br>
7.10 (d, 2H), 4.39-4.36 (m, 1H), 3.91-3.88 (m, 1H), 3.32-3.28 (m, 1H), 3.21-3.20 (m, 1H), 3.10-3.09 (m,<br>
1H), 2.92-2.91 (m 1H), 2.72-2.71 (m, 1H), 2.14-2.12 (m, 2H), 2.04-2.01 (m, 2H), 1.80-1.77 (m, 1H),<br>
1.63-1.53 (m, 1H), 1.47-1.41 (m, 4H); LRMS (ESI) TH/Z 735 (735 calcd for C32H3QC12F2N6O6S, M+H).<br>
EXAMPLE 33<br>
7V-(A/-r(3-Cvanobenzene')sulfonvll-4(J?Vr tej-t-butvl 1 '-pvrrolidine-2YVcarboxvlate1-(Uprolvl)-<br>
4-[(3",5"-dichloroisonicotinovDamino]-rLVphenvlalanine ethyl ester<br>
Utilizing the general procedure outlined in Example 1, Steps 2-3, 3,3-difluoropiperidine<br>
hydrochloride was exchanged for tert-butyl D-prolinate to give after preparative reverse phase HPLC<br>
purification (Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm, 20:80 â90:10 acetonitrile-water<br>
0.01% TFA), the title compound as a white solid: *H NMR (500 MHz, CDsOD) 5 8.63 (s, 2H), 8.55-8.54<br>
(m, IH), 8.13 (s, IH), 8.03-8.01 (m, IH), 7.87-7.85 (m, IH), 7.71-7.64 (m, 3H), 7.35-7.33 (m, 2H), 4.61-<br>
4.59 (m, 2H), 4.22-4.16 (m, 3H), 4.10-4.00 (m, IH), 3.88-3.84 (m, IH), 3.59-3.51 (m, 2H), 3.24-3.20 (m,<br>
2H), 3.04-3.01 (m, IH), 2.50-2.41 (m, IH), 2.26-2.22 (m ,2H), 2.12-2.10 (m, 2H), 2.00-1.94 (m, IH),<br>
1.50 (s, 9H), 1.25 (t, 3H); LRMS (ESI) mlz 814 (814 calcd for CsgfLtfCkNeOgS, M+H).<br>
EXAMPLE 34<br>
Ar-(A-[(3-Cvanobenzene')sulfonvn-4(J?V[fer/-butvl r-pvrrolidine-2YJ?)-carboxvlate1-(LVprolvl}-4-<br>
[(3 " .5 " -dichloroisonicotinoyBamino]-(LVphenvlalanme<br>
Utilizing the general procedure outlined in Example 2, the title compound was obtained<br>
from the compound of Example 33, after preparative reverse phase HPLC purification (Phenomenex<br>
Synergi 4u Max-RP 80A, 100 x 20.2 mm, 0:100 -&gt; 80:20 acetonitrile-water 0.01% TFA), as a white<br>
solid: 'H NMR (500 MHz, CDsOD) 5 8.62 (s, 2H), 8.47-8.45 (m, IH), 8.10 (s, IH), 8.02-8.00 (m, IH),<br>
7.81-7.79 (m, IH), 7.69-7.64 (m, 3H), 7.37-7.36 (m, 2H), 4.63-4.57 (m, 2H), 4.32-4.29 (m, IH), 4.15-<br>
4.05 (m, IH), 3.88-3.84 (m, IH), 3.68-3.60 (m, IH), 3.56-3.52 (m, IH), 3.31-3.26 (m, 2H), 3.02-2.98 (m,<br>
IH), 2.53-2.45 (m ,1H), 2.31-2.10 (m, 4H), 2.00-1.94 (m, IH), 1.50 (s, 9H); LRMS (ESI) mlz 786 (786<br>
calcd for CseHsgC^NeOgS, M+H).<br>
EXAMPLE 35<br>
A-(-rG-Cvanobenzenesulfonvn-4fvri'-pvrrolidine-2)-carboxvlicacid1-rLVprolvn-4-[f3".5'-<br>
dichloroisonicotinoyl)amino]-(LVphenylalanine<br>
To the solid compound of Example 34 (86 mg, 0.1 mmol), trifluoroacetic acid (2.5 ml)<br>
was added. After 4 h, the reaction was concentrated to give after preparative reverse phase HPLC<br>
purification (Phenomenex Synergi 4u Max-RP 80A, 100 x 20.2 mm, 0:100 â80:20 acetonitrile-water<br>
0.01% TFA), the title compound as a white solid: !H NMR (500 MHz, CDsOD) 5 8.62 (s, 2H), 8.48-8.47<br>
(m, IH), 8.10 (s, IH), 8.01-7.97 (m, IH), 7.82-7.80 (m, IH), 7.69-7.61 (m, 3H), 7.38-7.36 (m, 2H), 4.63-<br>
4.58 (m, 2H), 4.44-4.41 (m, IH), 4.22-4.12 (m, IH), 3.90-3.86 (m, IH), 3.69-3.62 (m, IH), 3.61-3.58 (m,<br>
IH), 3.33-3.26 (m, 2H), 3.03-2.98 (m, IH), 2.59-2.48 (m ,1H), 2.37-2.10 (m, 4H), 2.00-1.89 (m, IH);<br>
LRMS (ESI) m/z 730 (730 calcd for C32H3iCl2N6OgS, M+H).<br><br>
WHAT IS CLAIMED IS:<br>
1. A compound of formula Ror a pharmaceutically acceptable salt thereof, wherein:<br>
AisNorN+-O;<br>
X and Y are independently selected from halogen, Ci_3alkyl, and Ci-3alkoxy;<br>
R1 is selected from (1) hydrogen, (2) Ci_iQalkyl, (3) -(Cl-ioalkyl)-aryl, (4) -(C<br>
(5) -(Ci.ioalkyl)-OC(0)-Ci_ioalkyl, (6) -(Ci-i0alkTl)-OC(O)-aryl, (7) -(Ci-i0alkyl)-OC(O)OCi_<br>
ioalkyl, and (8) -(Ci_iQalkyl)-N+(Ci_3alkyl)3; wherein alkyl is optionally substituted with one to<br>
three substituents independently selected from Ra, and aryl is optionally substituted with one to three<br>
substituents independently selected from Rb;<br>
R is hydrogen or methyl;<br>
one of R3 and R4 is hydrogen, and the other is<br>
R5<br>
k is 0 to 4;<br>
R5 and R6 are independently selected from hydrogen, fluorine, CF3, and CO2R^, with the proviso that<br>
R5 and R6 are not both hydrogen;<br>
R? and R8 are independently selected from H, -SO2-Ci_3alkyl, CN, CF3, OCF3, and halogen;<br>
Ra is selected from (1) -ORd, (2) -NRdS(O)mRe, (3) -NO2, (4) halogen, (5) -SCOmRd, (6) -SRd,<br>
(7) -S(0)20Rd, (8) -S(0)raNRdRe, (9) -NRdRe, (10) -O(CRfRg)nNRdRe, (11) -C(O)Rd<br>
3 (12) -CO2Rd,<br>
(13) -CO2(CRfRg)nCONRdRe, (14) -OC(O)Rd, (15) -CN, (16) -C(O)NRdRe, (17) -NRdC(O)Re,<br>
(18) -OC(0)NRdRe, (19) -NRdC(O)ORe, (20) -NRdC(O)NRdRe, (21) -CRd(N-ORe), (22) CF3, (23) -<br>
OCF3, (24) C3-gcycloalkyl, and (25) heterocyclyl; wherein cycloalkyl and heterocyclyl are optionally<br>
substituted with one to three groups independently selected from Rc;<br>
Rb is selected from (1) a group selected from Ra, (2) CI.IQ alkyl, (3) C2-1Q alkenyl (4) C2-10 alkynyl,<br>
(5) aryl, and (6) -(Ci_ioalkyl)-aryl, wherein alkyl, alkenyl, alkynyl, and aryl are optionally substituted<br>
with one to three substituents selected from a group independently selected from Rc;<br>
Rc is (1) halogen, (2) amino, (3) carboxy, (4) Ci_4alkyl, (5) Ci_4alkoxy, (6) aryl, (7) -(Ci-4alkyl)-aryl,<br>
(8) hydroxy, (9) CFs, (10) OC(O)Ci-4alkyl, (11) OC(O)NRfRg, or (12) aryloxy;<br>
R and Re are independently selected from hydrogen, Ci-ioalkyl, C2-lQalkenyl, Co-lQalkynyl, Cy<br>
and -(Ci-ioalkyl)-Cy, wherein alkyl, alkenyl, alkynyl and Cy are optionally substituted with one to four<br>
substituents independently selected from Rc; or<br>
R and Re together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7<br>
members containing 0-2 additional heteroatoms independently selected from O, S and N-Rn;<br>
Rf and R8 are independently selected from hydrogen, Ci_i()alkyl, Cy and -(Ci-ioalkyl)-Cy; or<br>
Rf and R8 together with the carbon to which they are attached form a ring of 5 to 7 members containing<br>
0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;<br>
Rh is selected from Rf and -C(O)Rf;<br>
Cy is selected from cycloalkyl, heterocyclyl, aryl, and heteroaryl;<br>
m is 1 or 2; and<br>
n is 2 to 5.<br>
2. A compound of Claim 1 wherein one of X and Y is halogen and the other is<br>
selected from halogen, Ci_3alkyl and Cjalkoxy.<br>
3. A compound of Claim 1 wherein Rl is hydrogen, GI_<br>
4alkyl, -(Cialkyl)OCi_4alkyl or-(Ci_4alkyl)N+(Ci.3alkyl)3.<br>
4. A compound of Claim 1 wherein R3 is hydrogen, and R4 is<br>
or<br>
wherein one of R and R6 is F and the other is H or F, k is 0 to 4, and k' is 0 to 2.<br>
5. A compound of Claim 1 wherein R4 is hydrogen and R3 is<br>
rpQ<br><br>
k or<br>
wherein one of R and R6 is F and the other is H or F, k is 0 to 4, and k' is 0 to 2.<br>
6. A compound of Claim 1 having the formula la:<br>
or a pharmaceutically acceptable salt thereof, wherein<br>
A is N or N+O;<br>
Rl is selected from hydrogen, Ci_ioalkyl, -(C]-4alkyl)-aryl, -(Ci-4aIkyl)-O-C]-4alkyl, and<br>
-(Ci-4alkyI)-N+(Ci_3a!ky])3;<br>
one of R- and R4 is hydrogen and the other is selected from<br>
R5 , v D5 CF,<br>
wherein one of R5 and R6 is F and the other is H or F, k is 0 to 4, and k' is 0 to 2;<br>
R7 and R8 are independently selected from H, SO2-Ci_3alkyl, CN, CFs, OCF3, and halogen.<br>
7. A compound of Claim 6 wherein k is 0 to 2.<br>
8. A compound of Claim 6 wherein R3 is hydrogen and R4 is selected from 3,3-<br>
difluoro-l-azetidinyl, 3,3-difluoro-l-pyrrolidinyl and 3,3-difluoro-l-piperidinyl.<br>
9. A compound of Claim 7 wherein R? is 3-cyano and R8 is hydrogen.<br>
10. A pharmaceutical composition comprising a therapeutically effective amount of<br>
a compound of Claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable<br>
carrier.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LWFzc2lnbm1lbnRzLnBkZg==" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-assignments.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUNsYWltcy0oMjQtMDktMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Claims-(24-09-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUNvcnJlc3BvbmRhbmNlIE90aGVycy0oMTUtMDEtMjAxNSkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Correspondance Others-(15-01-2015).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMDQtMDgtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Correspondence Others-(04-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMDgtMDEtMjAxNSkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Correspondence Others-(08-01-2015).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMTUtMDctMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Correspondence Others-(15-07-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMTgtMDctMjAxNCkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Correspondence Others-(18-07-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMjYtMDYtMjAxNCkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Correspondence Others-(26-06-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMjgtMDEtMjAxNCkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Correspondence Others-(28-01-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTgtMDItMjAxMCkucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Correspondence-Others-(18-02-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTgtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Correspondence-Others-(18-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMjQtMDktMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Correspondence-Others-(24-09-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUNvcnJlc3BvbmRlbmNlLU90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Correspondence-Others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUZvcm0tMS0oMDgtMDEtMjAxNSkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Form-1-(08-01-2015).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUZvcm0tMS0oMTgtMDItMjAxMCkucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Form-1-(18-02-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUZvcm0tMTMtKDI0LTA5LTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Form-13-(24-09-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUZvcm0tMTgtKDA0LTA4LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Form-18-(04-08-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUZvcm0tMi0oMDgtMDEtMjAxNSkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Form-2-(08-01-2015).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUZvcm0tMi0oMTgtMDItMjAxMCkucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Form-2-(18-02-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUZvcm0tMi0oMTgtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Form-2-(18-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUZvcm0tMy0oMjQtMDktMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Form-3-(24-09-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUZvcm0tNS0oMTgtMDItMjAxMCkucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Form-5-(18-02-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUZvcm0tNS0oMTgtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-Form-5-(18-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUZvcm0tNi0oMDgtMDEtMjAxNSkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Form-6-(08-01-2015).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LUdQQS0oMTUtMDEtMjAxNSkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-GPA-(15-01-2015).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUdQQS0oMTgtMDItMjAxMCkucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-GPA-(18-02-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LUdQQS0oMTgtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-GPA-(18-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LU90aGVycy0oMDgtMDEtMjAxNSkucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-Others-(08-01-2015).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LXBjdC0yMTAucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-pct-210.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LXBjdC0yMjAucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-pct-220.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1ERUxOUC0yMDA3LVBDVC0yMzcucGRm" target="_blank" style="word-wrap:break-word;">1112-DELNP-2007-PCT-237.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LXBjdC0zMDYucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-pct-306.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LXBjdC0zMjYucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-pct-326.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTExMi1kZWxucC0yMDA3LXBjdC0zNzMucGRm" target="_blank" style="word-wrap:break-word;">1112-delnp-2007-pct-373.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Q2VydGlmaWNhdGVfb2ZfbWVyZ2VyX2Zyb21fTWVyY2tfdG9fU2NoZXJpbmcucGRm" target="_blank" style="word-wrap:break-word;">Certificate_of_merger_from_Merck_to_Schering.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SVBBMjQzMSBBbXJpc2gucGRm" target="_blank" style="word-wrap:break-word;">IPA2431 Amrish.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=U0NIRVJJTkcgQ09SUE9SQVRJT05fR1BPQSBMJlMucGRm" target="_blank" style="word-wrap:break-word;">SCHERING CORPORATION_GPOA L&amp;S.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="264695-novel-process-for-manufacture-of-lopinavir-ritonavir-tablets.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="264697-method-for-managing-means-for-accessing-conditional-access-data.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>264696</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1112/DELNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>04/2015</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>23-Jan-2015</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>15-Jan-2015</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>09-Feb-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>MERCK SHARP &amp;amp; DOHME CORP.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY 07065, UNITED STATES OF AMERICA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>CHEN, WEICHAO</td>
											<td>126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY 07065-0907</td>
										</tr>
										<tr>
											<td>2</td>
											<td>LEBSACK, ALEC, C</td>
											<td>126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY 07065-0907</td>
										</tr>
										<tr>
											<td>3</td>
											<td>MUNOZ, BENITO</td>
											<td>126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY 07065-0907</td>
										</tr>
										<tr>
											<td>4</td>
											<td>VENKATRAMAN, SHANKAR</td>
											<td>126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY 07065-0907</td>
										</tr>
										<tr>
											<td>5</td>
											<td>WANG, BOWEI</td>
											<td>126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY 07065-0907</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07K 5/078</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2005/028768</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-08-12</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/601,942</td>
									<td>2004-08-16</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/264696-vla-4-antagonists by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:27:52 GMT -->
</html>
